Metal exposures, endocrine factors and cancer risk by García García-Esquinas, Esther
 
 
 
Universidad Autónoma de Madrid 
Facultad de Medicina 
Departamento de Medicina Preventiva y Salud Pública 
 
 
 
 
 
 
METAL EXPOSURES, ENDOCRINE FACTORS AND CANCER RISK 
 
 
 
DOCTORAL THESIS 
 
 
 
 
 
 
 
Esther García García-Esquinas  
 
Directors: 
Dra. Marina Pollán Santamaría  
Dra. Ana Navas Acién  
 
 
Madrid, 2013 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
DOCTORAL THESIS 
 
 
 
 
 
METAL EXPOSURES, ENDOCRINE FACTORS AND CANCER RISK 
 
 
 
 
 
 
 
 
 
 
Exposición a metales, factores endocrinos y riesgo de cáncer 
 
Esther García García-Esquinas 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
  
  
 
 
Dr. Marina Pollán Santamaría and Dr. Ana Navas Acién, inform that the thesis entitled 
“Metal exposures, endocrine factors and cancer risk” is an original work carried out by 
Esther García García-Esquinas under our guidance and supervision. This is an original 
work and has not been submitted to any university for the awarding of any 
degree/diploma. We verify that we have read the thesis, that it is well written and it 
demonstrates a thorough understanding of the scientific methodology. 
 
 
 
 
 
 
 
Marina Pollán Santamaría, MD, PhD 
 
 
 
 
Environmental and Cancer  
Epidemiology Unit.  
National Centre for Epidemiology. 
Carlos III Institute of Health. 
 
Ana Navas Acien, MD, PhD  
 
 
 
 
Departments of Environmental Health 
Sciences and Epidemiology.  
Bloomberg School of Public Health.  
John Hopkins University. 
 Preface 
 
The present dissertation entitled “Metal exposures, endocrine factors and cancer 
risk” is the result of research performed in the last 3 years under the leadership of Esther 
García García-Esquinas in collaboration with members of the Departments of 
Environmental Health Science (Johns Hopkins Bloomberg School of Public Health), 
and Environmental and Cancer Epidemiology (National Center for Epidemiology, 
Institute of Health Carlos III).  
 
The dissertation is organized into 6 chapters as follows. Chapter 1 provides a 
general introduction. Chapter 2 describes the main hypothesis and objectives. Chapter 3 
gives an overview of the methods and study populations. Chapter 4 presents the main 
results: first, it evaluates the association of arsenic exposure and cancer mortality using 
data from a prospective cohort study in American Indians (Strong Heart Study); second, 
it investigates the association of cadmium exposure and cancer mortality in the Strong 
Heart Study; third it evaluates the possible effect of cadmium as a mediator on the 
association between cigarette smoking and cancer mortality; fourth it evaluates the 
association between several anthropometrical factors during lifetime and the risk of 
hormone-dependent tumors in a case-control study (MCC-Spain); and fifth it assesses 
the influence of diabetes, diabetes duration and diabetes treatment on the incidence of 
postmenopausal breast and prostate cancer in MCC-Spain. Chapter 5 provides a 
summary and discussion of the research findings, and chapter 6 completes the 
dissertation by presenting the main conclusions. 
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 Cancer is one of the leading causes of death both in men and women in the world, 
particularly in developed countries. Around 90% of cancers are linked to some type of 
environmental or lifestyle factor, including use of tobacco, consumption of certain foods or 
exposure to substances in air, water and soil. Cancer epidemiology studies have played an 
important role in identifying many of these environmental factors and translating this 
knowledge into prevention strategies. However, in spite of extensive investigations, some 
gaps in the state of knowledge exist, and for some cancers like prostate cancer, few 
environmental factors have been identified. The main objective of this thesis is to address 
the influence of some of these environmental and lifestyle factors on cancer development. 
  Data from a cohort study (Strong Heart Study) and a case-control study (MCC-
Spain) have been analyzed. The Strong Heart Study is the largest epidemiologic study of 
cardiovascular disease in American Indian populations ever undertaken. Initially conducted 
in 1989 to 1991, the Strong Heart Study recruited 4,549 participants from 13 tribes and 
communities in Arizona, Oklahoma, North and South Dakota and followed them up 
through 2008. MCC-Spain is a population-based multicase-control study that recruited 
incident, histologically confirmed cases of breast (N=1743) and prostate (N=1113) cancers 
from 22 Spanish public hospitals between 2008 and 2013. Controls (N=1880 for breast and 
1460 for prostate) were frequency-matched to the cases, taking into account age, sex and 
region. This thesis first evaluates the association between low-to-moderate levels of 
exposure to certain metals (arsenic and cadmium) and cancer mortality in the Strong Heart 
Study population, using Cox proportional hazards models. Then, it investigates the role of 
diabetes and obesity in the development of hormone-dependent tumors (breast and 
prostate) in MCC-Spain, using logistic mixed models that included the interviewer or the 
study region as random effect terms. 
 The median (interquartile range) urine concentration for inorganic plus methylated 
arsenic species was 9.7 (5.8-15.9) µg/g creatinine. The adjusted hazard ratios (95%CI) 
comparing the 80
th
 versus 20
th
 percentiles of arsenic were 1.14 (0.92-1.41) for overall 
cancer, 1.56 (1.02-2.39) for lung cancer, 1.34 (0.66-2.72) for liver cancer, 3.30 (1.28-8.48) 
for prostate cancer and 0.44 (0.14-0.96) for lymphatic and hematopoietic cancers. The 
median (interquartile range) urine cadmium concentration was 0.93 (0.61-1.46) µg/g 
creatinine. The adjusted hazard ratios (95%CI) comparing the 80
th
 versus 20
th
 percentiles 
of cadmium were 1.30 (1.09-1.55) for total cancer mortality, 2.27 (1.58-3.27) for lung 
cancer and 2.40 (1.24-1.96) for pancreas cancer mortality. 
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 In postmenopausal women, the age at maximum height was inversely associated 
with the risk of breast cancer (OR per year:0.93; 95%CI:0.89-0.98), while an overall 
increased risk of this tumor was observed with increasing body mass index (OR2 units:1.10; 
95%CI:1.05-1.15), waist circumference (OR10 cm : 1.04; 95%CI:0.99-1.20) and waist to hip 
ratio (OR0.10 units:1.20; 95%CI:1.03-1.41). In premenopausal women, the weight at age 45 
(OR5 kgs:1.13; 95%CI:1.00-1.28) and the waist circumference were associated with breast 
cancer risk (OR10 cm waist circumference:1.18; 95%CI:0.98-1.42) after adjustment for body mass 
index. By intrinsic subtypes, in postmenopausal women weight gain since age 20 was 
associated with an increased risk of HR+/HER2- tumors in models that did not account for 
body mass index (OR5 kg:1.10; 95%CI:1.04-1.16), while displayed a negative association 
with HER2+ tumors ( p heterogeneity of effects= 0.05). Those variables associated to 
obesity earlier in like (“weight at age 20” and “age at maximum weight) were associated 
with a decreased risk of more aggressive tumor subtypes (HER2+ and triple negative) in 
premenopausal but not postmenopausal women. In men, the age at maximum weight (OR5 
years: 1.05; 95%CI: 1.00-1.10) and the waist to hip ratio (OR0.1 units:1.21; 95%CI:1.03-1.43) 
were associated with the risk of high-grade prostate tumors. 
 Self-reported diabetes was associated with an increased risk of triple negative 
breast tumors in postmenopausal women (OR:2.13; 95%CI:1.25-3.63). In this group of 
women, metformin use was associated with a decreased risk of HR+/HER2- tumors (ORper 
year:0.89; 95%CI:0.80-0.99), while use of sulfonylurea was associated with an increased 
risk of triple negative tumors (ORper year:1.10; 95%CI:1.00-1.20). Finally, an increased risk 
of postmenopausal breast cancer was observed in women under insulin treatment 
(OR:2.14; 95%CI:1.13-4.09), with a non-significant positive dose response association 
between years of insulin use and breast cancer risk (ORper year:1.10; 95%CI:0.98-1.23). For 
prostate cancer, a decreased risk of low-grade tumors was observed in men with diabetes 
(OR:0.70; 95%CI:0.46-0.90), and this protective effect was stronger as time since 
diagnosis increased (ORper year:0.94; 95%CI:0.87-1.00). 
 These results provide novel evidence about the influence of low-moderate arsenic 
and cadmium exposure levels on cancer mortality. Additionally, regarding the association 
of obesity and diabetes with hormone-dependent cancers (breast and prostate), they offer 
valuable information suggesting differences in the effect of these factors by tumor subtype. 
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 El cáncer es una de las principales causas de muerte en el mundo, particularmente 
en países desarrollados. Alrededor del 90% de los cánceres están relacionados con factores 
ambientales o estilos de vida, como por ejemplo la exposición a tabaco, el consumo de 
ciertos alimentos o la exposición a substancias tóxicas a través del aire, el agua o el suelo. 
Los estudios epidemiológicos ponen de manifiesto la importancia de los factores 
ambientales en el desarrollo del cáncer, facilitando el diseño de estrategias preventivas. A 
pesar de la cantidad de investigación existente hasta la fecha, hay todavía lagunas en el 
conocimiento, y para algunos tumores como el de próstata, se desconocen muchos de los 
agentes ambientales implicados. El objetivo de esta tesis doctoral es conocer la influencia 
de algunos de estos factores ambientales o estilos de vida en el desarrollo del cáncer.  
 Se han analizado datos de un estudio de cohorte (Strong Heart Study) y de un 
estudio de casos y controles (MCC-Spain). El Strong Heart Study es el estudio 
epidemiológico más grande sobre enfermedad cardiovascular realizado hasta la fecha en 
indios americanos. Durante los años 1989 y 1991 se reclutaron 4,549 participantes de 13 
tribus y comunidades de Arizona, Oklahoma, Dakota de Norte y Dakota del sur, a los que 
se siguió hasta el año 2008. MCC-Spain es un estudio multicaso-control de base 
poblacional que reclutó durante los años 2008-2013, casos incidentes e histológicamente 
confirmados de cánceres de mama (N=1743) y próstata (N=1113) en 22 hospitales 
públicos españoles. Los controles (N=1880 para mama y 1460 para próstata) fueron 
apareados por frecuencia con los casos según grupos de edad, sexo y nodo de 
reclutamiento. Esta tesis evalúa en primer lugar la asociación entre la exposición a dosis 
bajas-moderadas de algunos metales (arsénico y cadmio) y la mortalidad por cáncer en el 
estudio Strong Heart Study, utilizando para ello modelos de riesgos proporcionales de Cox. 
Posteriormente, investiga el papel de algunos factores endocrinos (obesidad y diabetes) en 
el desarrollo de tumores hormono-dependientes (mama y próstata) en participantes del 
estudio MCC-Spain, utilizando para ello modelos mixtos de regresión logística que toman 
como efecto de términos aleatorios al entrevistador o al nodo reclutador. 
 La mediana (rango intercuartílico) de arsénico inorgánico y sus especies metiladas 
en orina fue de 9.7 (5.8-15.9) µg/g creatinina. Las hazard ratios (IC95%) comparando los 
percentiles 80 y 20 de la distribución de arsénico fueron 1.14 (0.92-1.41) para mortalidad 
global por cáncer, 1.56 (1.02-2.39) para mortalidad por cáncer de pulmón, 1.34 (0.66-2.72) 
para mortalidad por cáncer de hígado, 3.30 (1.28-8.48) para mortalidad por cáncer de 
próstata y 0.44 (0.14-0.96) para mortalidad por tumores del sistema linfohematopoyético. 
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 La mediana (rango intercuartílico) de cadmio en orina fue de 0.93 (0.61-1.46) µg/g 
creatinina. Las hazard ratios (IC95%) comparando los percentiles 80 y 20 de la 
distribución de cadmio fueron 1.30 (1.09-1.55) para mortalidad global por cáncer, 2.27 
(1.58-3.27) para cáncer de pulmón y 2.40 (1.24-1.96) para mortalidad por cáncer de 
páncreas. 
 En mujeres postmenopáusicas, la edad de máxima altura se relacionó inversamente 
con el riesgo de padecer cáncer de mama (ORaño:0.93; 95%IC:0.89-0.98), mientras que se 
observó un incremento del riesgo de padecer este tumor en mujeres con un mayor índice de 
masa corporal (OR2 unidades:1.10; 95%CI:1.05-1.15), una mayor circunferencia de cintura 
(OR10 cm :1.04; 95%CI:0.99-1.20) o un mayor índice de cintura-cadera (OR0.10 unidades:1.20; 
95%CI:1.03-1.41). En mujeres premenopáusicas, el peso a los 45 años (OR5 kgs:1.13; 
95%CI:1.00-1.28) y el tamaño de la circunferencia de la cintura se asociaron con un 
incremento del riesgo de cáncer de mama (OR10 cm cintura :1.18; 95%CI:0.98-1.42). Por 
subtipos tumorales, en mujeres postmenopáusicas la ganancia de peso desde los 20 años se 
asoció con un incremento del riesgo de padecer tumores RH+/HER2- en aquellos modelos 
que no tenían en cuenta el índice de masa corporal (OR5 kg:1.10; 95%CI:1.04-1.16), y con 
un decremento del riesgo de padecer tumores HER2+ (p heterogeneidad de efectos= 0.05). 
Las variables relacionadas con la obesidad a edades más tempranas de la vida (“peso a los 
20 años” y “edad de alcance del peso máximo”) se asociaron con un decremento del riesgo 
de algunos subtipos tumorales (HER2+ y triples negativos) en mujeres premenopáusicas, 
pero no en mujeres postmenopáusicas. En los varones, la edad a la que se alcanzó el peso 
máximo (OR5 años:1.05; 95%CI: 1.00-1.10) y el índice de cintura cadera (OR0.1 unidades:1.21; 
95%CI:1.03-1.43) se asociaron con el riesgo de padecer tumores de próstata de alto grado. 
 La diabetes auto-reportada se asoció con un incremento del riesgo de padecer 
tumores triple negativos en mujeres postmenopáusicas (OR:2.13; 95%CI:1.25-3.63). En 
este grupo de mujeres, el uso de metformina se asoció con un menor riesgo de desarrollar 
tumores RH+/HER2- (ORpor año:0.89; 95%CI:0.80-0.99), mientras que el tratamiento con 
sulfonilureas se relacionó con un incremento del riesgo de padecer tumores triple negativos 
(ORpor año:1.10; 95%CI:1.00-1.20). Por último, se observó un incremento del riesgo de 
cáncer de mama en mujeres postmenopáusicas que utilizaron insulina (OR:2.14; 
95%CI:1.13-4.09), siendo también positiva (aunque no significativa) la asociación con el 
número de años en tratamiento con este fármaco (ORpor año:1.10; 95%CI:0.98-1.23). Los 
varones diabéticos tuvieron un menor riesgo de padecer tumores de próstata de bajo grado 
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(OR:0.70; 95%CI:0.46-0.90), y este efecto protector era más marcado con el paso del 
tiempo desde el diagnóstico inicial de diabetes (ORpor año:0.94; 95%CI:0.87-1.00). 
 Estos resultados aportan nueva evidencia sobre la influencia de la exposición a 
niveles bajos-moderados de arsénico y cadmio en la mortalidad por cáncer. Además, en 
relación a la asociación entre obesidad y diabetes con los tumores hormono-dependientes 
(mama y próstata), proporcionan información valiosa que sugiere un efecto diferencial de 
estos factores por subtipo tumoral. 
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1.1 Cancer Epidemiology 
The art of epidemiological thinking is to draw conclusions from imperfect data 
-George W. Comstock – 
                                                                                                    (1915-2007) 
 
 
1.1.1 The burden of cancer 
1.1.1.1 A look at the global burden of cancer 
 
 Cancer is one of the leading causes of death both in men and women in the world, 
particularly in developing countries (1). The most common cancers worldwide are lung, 
breast, large intestine (colon and rectum), stomach and prostate, with lung cancer 
accounting for most deaths. Based on the GLOBOCAN 2008 estimates, around 12.7 
million new cancer cases and 7.6 million cancer deaths occurred in 2008 (2). One quarter 
of this global burden was located in Europe (3). 
 
Figure 1.1: Estimated new cancer cases and deaths worldwide for leading cancer sites. GLOBOCAN, 2008. 
Source: Jemal A. et al. Global cancer statistics. CA Cancer J.Clin. 2011;61:69-90.  
 
 By 2030, the world population is expected to have increased to more than 8 billion. 
During this same year, approximately 26 million new cancer cases will be diagnosed, and 
17 million cancer patients will die (4). Given the magnitude of these trends, we need to 
better characterize the effects of specific risk factors on cancer development, as well as to 
improve our efforts to control well known modifiable causes of cancer such as cigarette 
smoking, physical inactivity or poor nutrition (1).  
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1.1.1.2  Cancer burden in Spain 
 In Spain, incidence data come from local population-based cancer registries that 
represent around 30% of the total population (5). Twelve of these registries (Zaragoza, 
Navarre, Tarragona, Murcia, Granada, Basque Country, Mallorca, Albacete, Asturias, 
Canary Islands, Cuenca, Girona) contribute to the Cancer Incidence in Five Continents 
series edited by IARC (6). Based on these series, the GLOBOCAN project estimated 
 
   
      Figure 1.2: Estimated new cancer cases and deaths in Spain for leading cancer sites. Source: Globocan 2008. 
 
that around 196,902 cancers (excluding non-melanoma skin cancer) occurred in this 
country during 2008. The most frequent locations were prostate, lung and colorectum in 
men; and breast, colorectum and corpus uteri in women. During this same year, lung and 
colorectal tumors contributed to 40% of all cancer deaths in men, while those of the breast 
and lung caused most cancer deaths in women.  
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1.1.1.3  Cancer burden in the US general population and in American Indian 
communities 
 
 In the US, the American Cancer Society, the Centers for Disease Control and 
Prevention and the North American Association of Central Cancer Registries provide 
annual estimations on cancer occurrence and trends. According to these estimations, 
approximately 1.6 million new cancer cases and 600,000 cancer deaths occurred in 2012. 
 
 
Figure 1.3: Ten leading cancer types for the estimated new cancer cases and deaths by sex, United States, 2012. 
Source: Siegel R. et al. Cancer statistics, 2012. CA Cancer J.Clin. 2012;1:10-29.  
 
The three most commonly diagnosed types of cancer in men were those of the prostate, 
lung/bronchus, and large intestine; while in women breast, lung/bronchus and colorectal 
cancers were the most frequent. Four sites accounted for more than 25% of all cancer 
deaths: lung/bronchus, prostate and colorectum in men, and lung/bronchus, breast and 
colorectum in women. 
 
 Wide regional variation is characteristic of American Indian cancer surveillance 
and it is difficult to provide a comprehensive picture of the global burden of cancer in their 
communities. Studying these populations is difficult because of racial misclassification in 
medical charts and important disparities associated with lack of health care coverage and 
16 
 
low socioeconomic status. According to the last estimates from the Office of Minority 
Health (US Department of Health and Human Services), in 2009 the incidence of cancer 
was 0.8 times lower in American Indians than in Non-Hispanic Whites (7). However, 
certain types of cancers such as those of the liver, stomach or colorectum, were twice as 
frequent in American Indians than in the American general population (8). Complex 
factors are probably contributing to racial disparities, including a range variation in the 
prevalence of behavioral risk factors for cancer such as tobacco smoke, physical inactivity, 
obesity or excessive alcohol consumption; access to high-quality screening or treatment. 
Despite this unequal burden, few epidemiologic studies have focused in this racial group, 
and the specific cancer risk factors in these populations are unknown (8). 
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1.1.2 Environmental factors in cancer development 
Genes are absolutely not our fate 
                       -Craig Venter- 
                                                                                                   (1946 - ) 
 
 
 Cancer is a chronic disease caused by environmental factors and their interaction 
with genes. It has been estimated that around 90-95% of cancer cases are directly 
attributable to environmental and lifestyle risk factors, while only 5-10% have an 
hereditary origin (9). However, despite remarkable advances in cancer research during the 
last century, very little is known about the exact environmental risk factors affecting many 
tumors (10). 
 
Figure 1.4 Conceptual framework showing the complex relationship between the different studied environmental and 
lifestyle factors and cancer risk. 
  
 The importance of the environment in cancer development was first revealed by 
migration studies showing that cancer rates in migrants from low cancer incidence 
countries soon converged to that of the new country (11;12). Later, studies on monozygotic 
and dizygotic twins have confirmed that inherited genetic factors make a small 
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contribution to the risk of most cancers types and have shown that even when strong 
heritable factors exist, the environment acts as the overwhelming contributor to cancer 
development (13). 
 Exposure to environmental hazards increases the risk of cancer because they are 
able to interfere with biological processes. As examples, some agents can alter DNA 
through genetic or epigenetic changes, leading to activation of oncogenes or inactivation of 
tumor suppressor genes. Progressive accumulation of mutations in these genes will 
promote transformation of cells to a malignant state. Other environmental contaminants 
can damage the immune system breaking the equilibrium that allows the internal 
environment to control survival and proliferation of mutated cells. Finally, certain agents 
may also affect the synthesis and function of internal hormones, which maintain the normal 
function of numerous biologic processes. 
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1.2 Metals and cancer 
 
1.2.1 Arsenic 
 
 Arsenic is a naturally occurring element widely distributed in the earth´s crust. It is 
present in two main forms: inorganic (arsenite and arsenate) and organic (arsenobetaine, 
arsenosugars…) compounds. The sources of exposure, biotransformation in the human 
body and toxicity of inorganic and organic arsenic differ substantially.  
 
1.2.1.1  Exposure  
 Main sources of inorganic arsenic exposure in the general population include 
drinking water and certain foods (e.g. rice, grains or juices) (14;15). In seafood, arsenic is 
mainly found in its less toxic organic form arsenobetaine (16), although some seafood 
species are also rich in arsenosugars and these can be metabolized to several inorganic 
arsenic species, mainly DMA. 
 Inorganic arsenic is released to water from natural erosion of rocks or from 
agricultural and industrial processes. Additionally, certain anthropogenic sources (i.e. 
nonferrous metal mining, pesticide application or coal combustion) can also contaminate 
water with arsenic. The current safety standard for arsenic in drinking water established by 
the World Health Organization, the US Environmental Protection Agency (USEPA) and 
the European Union is 10 µg/L (17;18), but there are concerns that this limit may be too 
high to protect human populations from excess cancer risk (19). 
 
1.2.1.2  Specific sources of arsenic in American Indian communities 
  In the US, inorganic arsenic exposure through drinking water disproportionately 
affects certain rural communities from the Western states, including Native Americans 
(20). Participants in the Strong Heart Study relied either on small public water systems or 
on private wells. In Arizona and North and South Dakota, arsenic concentrations in public 
drinking water systems for the studied communities at the time of the study ranged from 
<10 to 61 µg/L in Arizona and from <10 µg/L up to 21 µg/L in North and South Dakota. 
Levels in private wells are not known but given arsenic concentrations in groundwater in 
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these regions (20), it is likely that levels exceeded 10 and even 50 µg/L. As estimated for 
other populations with arsenic levels in drinking water <10 µg/L, we expect that diet is the 
main source of arsenic exposure in Oklahoma (21). 
 
1.2.1.3 Biotransformation  
 Both organic and inorganic arsenic are well absorbed in the gastrointestinal tract, 
and then widely distributed in the body. There are very few data on the availability of 
arsenic after inhalation or dermal exposure, although it is estimated that around 75-85% is 
absorbed after inhalation and <1% after dermal exposure (22). Once absorbed into the 
body, organic arsenic is not metabolized but is rapidly excreted in the urine (23). 
Controversially, inorganic arsenic is methylated into monomethylarsenate (MMA) and 
dimethylarsenate (DMA) which are excreted in urine together with organic arsenic. This 
methylation is considered to be critical in arsenic toxicity. The average distribution of 
arsenic metabolites in urine is approximately of around 10-30% for inorganic arsenic 
(arsenate and arsenite), 10-20% for MMA and 60-80% for DMA (24). Although the 
excretion pattern for each individual is fairly constant over time, inter-individual 
differences in the methylation process may influence the proportion of inorganic and 
organic concentrations in urine. Smoking and drinking alcohol seem to reduce the 
efficiency of the second methylation step resulting in a higher MA/DMA ratio in urine. 
Men also tend to have higher MA/DMA than women. Finally, there is some suggestion 
that nutritional deficiencies, such as folate deficency, can modify arsenic methylation 
capacity (25).  
 
1.2.1.4  Urine arsenic as a biomarker of exposure 
 Urinary arsenic is the biomarker of choice for epidemiological studies (23). This is 
because compared to other biomarkers such as hair, toenail or blood, urine arsenic gives 
the possibility to assess arsenic biotransformation, as reflected by arsenic species in urine 
samples. Additionally, arsenic in urine shows a good correlation with levels in drinking 
water (26). Generally levels of overall arsenic in the urine of non-exposed populations are 
<50 μg/L (23), although these can vary related to arsenic levels in drinking water and to 
seafood intake. Increased arsenic clearance is seen in males (27;28), smokers (27) and 
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people having lower BMI (29), while decreased (30) or similar levels (27) have been found 
with increasing age. 
 
 
Figure 1.5: Main steps on arsenic metabolism. 
 
1.2.1.5  Health effects 
  Inorganic arsenic is generally more harmful for human health than its organic 
forms. Long-term exposure to inorganic arsenic has been associated with skin lesions (31), 
cardiovascular disease (32), diabetes (33;34), developmental (35) and reproductive 
problems (36). Additionally, arsenic exposure can lead to cancer development.  
Based on human epidemiological data, the International Agency for Research on 
cancer (IARC) established a causal role for arsenic on skin, lung and bladder cancers, and 
showed suggestive although limited evidence for liver, kidney and prostate cancers (37). 
Key epidemiological evidence came from populations chronically exposed to high arsenic 
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levels in drinking water (>150 µg/L) in southwestern Taiwan (38), Bangladesh (39), 
northern Chile (40), and Argentina (41).   
The evidence at low-moderate arsenic levels remains limited for most cancers, and 
the few epidemiological studies that have addressed this issue are mostly ecological or 
retrospective (42).  
 
1.2.1.6 Mechanistic evidence for arsenic carcinogenesis 
 Evidence for carcinogenicity exists for several arsenic species including inorganic 
arsenic (arsenite and arsenate) and methylated species (trivalent and pentavalent MMA and 
DMA), with trivalent arsenic species generally believed to be more toxic. However, the 
exact mechanisms for arsenic carcinogenicity remain unclear. A major challenge has been 
to develop animal models for arsenic carcinogenesis, with transplacental models being 
essential to advance our understanding (43). Some of the accepted mechanisms involve 
genetic and epigenetic changes, oxidative stress, enhanced cell proliferation, mitochondrial 
damage and modulation of gene expression (44-47).  
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1.2.2 Cadmium 
 
1.2.2.1 Exposure 
 Cadmium pollution in soil, air and water is ubiquitous due to its use in industrial 
products (batteries, coatings and plastic stabilizers), contamination of phosphate fertilizers, 
and release from motor vehicle fuel combustion and tire way (48). Soil contamination is a 
major health problem because leafy/root vegetables and grains bio-concentrate cadmium 
(49), resulting in major sources of this metal exposure through diet and smoking (50). For 
this reason, in smokers, tobacco is the main source of cadmium exposure, while in the non-
smoking general population living in non-polluted settings, diet is the main source of 
exposure (51). 
 
1.1.1.1.1 Specific sources of cadmium in American Indian communities 
 In Native American populations from North America, relevant sources of cadmium 
exposure include living in the vicinity of contaminant plants and mining areas (52;53) and 
surface-dust in jewelry-making homes (54). Small scale motor vehicle repair is another 
activity that could be relevant for cadmium exposure in these communities (55). 
 
1.2.2.2 Biotransformation 
 Around 25-50% of inhaled cadmium is absorbed (56). Estimated rates of absorption 
after ingestion are 5% for men and 10% for women (56). This variability among sexes is 
attributed to the lower iron stores in women, as cadmium and iron are both absorbed in the 
intestine by the divalent metal transporter 1 (57). In the human body, cadmium binds to 
metallothionein, believed to play an important role in preventing cadmium toxicity, but 
also responsible for long-term bioaccumulation of this metal in different tissues, 
particularly in kidney and liver (58). Only a small fraction of cadmium (~5%) is excreted, 
while the rest accumulates in the body (56).  
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1.2.2.3 Urine cadmium as a biomarker of exposure  
  Urine cadmium is often used as a measure of long-term exposure, as it is 
proportional to the body burden of this metal. In this sense, age has always been 
considered one of the most important determinants of urine cadmium concentrations (56). 
However, new studies suggest that at low levels of exposure, cadmium may be highly 
influenced by recent intake (59). Generally, levels of cadmium in the urine of non-exposed 
populations are < 1µg/g creatinine, although these can be much higher in smokers (56). 
Variations in diuresis or glomerular filtration may affect urine cadmium (59), particularly 
in individuals with kidney damage (56).  
 
1.2.2.4 Health effects 
 Kidneys and bones are major targets for cadmium toxicity. Dose-response 
assessment using early markers of kidney damage, identify urinary cadmium limits of 
departure for kidney effects between 1.5 and 3.2 µg/g creatinine (60), similarly to those 
described for bone injury (61). Long-term cadmium exposure has also been associated with 
increased risk of reduced bone mineral density and bone fractures (62), renal damage (63), 
hypertension (64;65), diabetes (66), peripheral artery disease (67;68) and coronary heart 
disease (69). 
 Cadmium was classified as a human carcinogen by IARC in 1993 (70). Since then, 
results from epidemiological studies in cadmium polluted areas and occupationally 
exposed populations have strengthen the evidence that cadmium exposure increases the 
risk of lung cancer (71-73). In occupationally exposed women, some (74) but not all (71) 
studies have found an increased risk of breast cancer. For prostate cancer, although a 
number of early epidemiological studies reported an increased risk among cadmium 
workers (75;76), the evidence is still inconsistent. Some studies also support occupational 
cadmium exposure to be a risk factor for kidney (77) and pancreatic cancer (78).  
 Less is known about the carcinogenic effects of cadmium at low-moderate levels of 
exposure. In the Third National Health and Nutrition Examination Survey (1988-1994), 
urine cadmium was associated with overall cancer mortality over 13.5 years of follow-up 
(79). In men, cadmium was associated with cancers of the lung, pancreas and non-Hodking 
lymphoma but not with prostate cancer; while in women it was associated with cancers of 
the lung, ovaries, uterus and leukemia, but not with breast cancer. Cadmium exposure, 
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however, has been associated with breast cancer in women from general populations in 
Sweden (80) and the US (81;82). 
 
1.2.2.5 Mechanistic evidence for cadmium carcinogenesis  
 Proposed mechanisms for cadmium carcinogenicity include oxidative stress (83-
86), inhibition of DNA repair systems (87-89), apoptosis (90), epigenetic modifications 
affecting gene transcription (83;91) or endocrine disruption (92). It has been suggested that 
cadmium may act differently in different tissues (93), through differential induction of 
metallothionein expression (94). In human airway epithelial cells, cadmium can promote 
inflammation through cytokines (95) and increased reactive oxygen species formation (96). 
In vitro, chronic exposure of human pancreatic duct epithelial cells to cadmium results in 
malignant cell transformation with increased secretion of metalloproteinases, increased 
invasiveness and colony formation (97).    
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1.3 Obesity 
Except for smoking, obesity is now the number one preventable cause of death 
- Dr. C. Everett Koop- 
                                                                                                       (1916-2013) 
 
 
1.3.1 Global burden of obesity 
 The prevalence of overweight and obesity is increasing worldwide at an alarming 
rate, as a result of changes in dietary patterns and reductions in physical activity. Over the 
past three decades, the prevalence of obesity has doubled from 6.4% to 12%, and the 
prevalence of overweight has changed from 24.6 to 34.4%. If recent trends continue, it is 
estimated that by 2030, 38% of the overall population will be overweight and 20% obese 
(98).  
 
    Figure 1.6 : Prevalence of obesity (BMI≥ 30 kg/m2) in adults in 2008. Source: World Health Organization, 2011. 
 
 The prevalence of obesity differs remarkably across countries and it has reached 
epidemic magnitudes in some regions of the world. Very high prevalence of adult obesity 
can be observed in North America, Mexico or some countries of the Arab Gulf. In Europe, 
the highest prevalence is observed in eastern states and in some specific western countries 
such as the UK or Spain.  
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1.3.2 Measures of obesity in epidemiological studies 
 BMI has traditionally been the most commonly used marker of obesity in 
epidemiological studies, even if it has a poor sensitivity in finding excessive adiposity as it 
does not account for differences in body fat and muscle mass (99;100). Consequently, 
people with too much adiposity can be misclassified as non-obese based on their BMI (99). 
Waist circumference (WC) and waist-to-hip ratio (WHR) are central adiposity markers 
able to capture excesses in adipose tissue in subjects with normal BMI, and have been 
shown to be better risk predictors of obesity-related syndromes and all-cause mortality 
(100).  
 Other methods to estimate total body fat mass such as DXA (Duel-energy X-ray 
Absorptiometry), CT (Computed Tomography) or MRI (Magnetic Resonance Imagining) 
are generally too costly and complex to be used in large epidemiological studies (101). 
 
1.3.3 Health effects 
 
 According to the World Health Organization, overweight and obesity account for 
more than 2.8 million deaths each year and 2.3% of global DALYs. Overweight and 
obesity have been associated with the risk of diabetes (102), coronary heart disease (103), 
high blood pressure (104), high cholesterol (104), stroke (103) and obesity-hypoventilation 
syndrome (105). 
 
 In 2002, IARC concluded that people who are overweight or obese are at increased 
risk of certain tumors including those of the colorectum, breast (in postmenopausal 
women), oesophagus, endometrium and kidney. Since then, many epidemiological studies 
have been published showing a link between obesity and the risk of liver (106), gallbladder 
(107), bladder (108), ovarian (109), thyroid (110) or aggressive prostate tumors (111). 
Overall, it has been estimated that overweight and obesity could account for up to 15-20% 
of all cancer cases (112). 
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1.3.4 Mechanistic evidence for the link between excessive body fatness and cancer 
risk 
 Obesity is associated with hyperglycemia and insulin resistance (113). Both factors 
promote the synthesis and biological activity of IGF-1, which in turn can stimulate cell 
growth proliferation and survival through the PI3K/Akt pathway (113). Additionally, 
insulin and IGF-1 influence the bioavailability of sex steroids by reducing the hepatic 
concentrations of sex-hormone binding globulin (SHBG) and this mechanism is thought to 
play a major role in the genesis of certain hormone-dependent tumors (101). In this sense, 
reductions in SHBG lead to increased levels of both estradiol and testosterone in women. 
In men, only estradiol levels are increased while SHBG reductions inhibit testosterone 
synthesis. Additionally, in severely obese men, the increased levels of estradiol activate the 
hypothalamic estrogen receptors further inhibiting the gonadotropic stimulation of 
testicular testosterone production (114).  
 Emerging evidence points to an important role of local inflammation on cancer 
development. In obesity, adipocyte hypertrophy is associated with increased levels of free 
fatty acids that stimulate the NF-kB pathway in macrophages. Through this mechanism, 
the activated macrophages release tumor necrosis factor which facilitates the release of 
more fatty acids creating a paracrine loop that contributes to maintaining the 
proinflammatory state necessary for tumor carcinogenesis (113). Increased levels of leptin, 
the main pro-inflammatory adipokine secreted by the adipose tissue, and decreased levels 
of adiponectin, a hormone with important antitumoral effects, have also been proposed as 
important factors in the development of many cancers, including those of the breast and 
prostate (115;116). Finally, increased levels of VEGF and other proangiogenic factors (i.e. 
PAI-1) have shown to promote tumor growth and facilitate the metastatic spread of cancer 
cells (113). 
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1.4 Diabetes and cancer 
Three horses draw the diabetic chariot and their names are diet, exercise and insulin. 
 
-Elliott Proctor Joslin- 
                                                                                                 (1869-1962) 
 
 
1.4.1 Global burden of disease 
 Diabetes mellitus is a leading causes of death and disability worldwide (117). In 
2011, an estimated 366 million people had diabetes, and according to current projections 
from the International Diabetes Foundation, by 2030 this number will have risen to 552 
(118). Reasons for this dramatic increase are similar to those described for obesity and 
include aging, urbanization, sedentary lifestyles and poor nutrition.  
 
Figure 1.7 : Prevalence of diabetes in adults in 2011. Source: Diabetes Atlas, 2012. 
  
 Around 80% of diabetic individuals live in low- and middle- income countries, 
where diabetes is already an epidemic (118). Countries like China, India, US, Russia, 
Brazil, Bangladesh or Mexico face the greatest burden of diabetes. In Europe, with an 
estimated 52.6 million cases of diabetes in 2011, the countries with the highest prevalence 
are located in the eastern regions, including Poland, Belarus or Latvia. Conversely, the 
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highest number of people with diabetes are observed in the western countries like 
Germany, Italy or Spain (119). 
 
1.4.2  Health effects  
 According to the International Diabetes Foundation, in 2011 around 4.6 million 
adults died from diabetes or its complications, and around 50% of these deaths occurred in 
individuals under the age of 60 (118). Diabetes has been associated with an increased risk 
of microvascular complications (120), heart failure (121), stroke (121), peripheral artery 
disease (121), chronic kidney disease (122) and obstructive sleep apnea (123). 
  Substantial evidence increasingly supports that type-2 diabetes is a risk factor for 
the development of numerous types of cancers, including those of the pancreas, liver, 
stomach, colorectum, kidney, bladder, postmenopausal breast and endometrium (124;125). 
In contrast, a reduced incidence of prostate cancer has been observed in diabetic 
individuals (126). Still, a number of important questions remain unanswered. First, it is 
unclear whether the association between diabetes and cancer can be attributed to the 
existence of common risk factors for both diseases (i.e.: age, obesity, lack of physical 
activity), or to the direct effect of insulin resistance and its compensatory hyperinsulinemia 
and hyperglycaemia. Second, the latency period from diabetes exposure to cancer risk is 
unknown. Because changes in glucose concentrations, insulin sensitivity or insulin 
secretion can precede diagnosis of diabetes to up to 6 years (127), the increased risk of 
cancer could also predate clinical diagnosis of diabetes (128). Finally, anti-diabetes 
medication may also modulate the risk of cancer, and more research is needed to 
disentangle the effects of diabetes from those derived from its treatment (125). This is even 
more difficult if we take into account that most diabetic patients are treated with more than 
one glucose-lowering drug at the same time (129), and that treatment schemes change over 
the course of the disease according to its severity (130).  
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1.4.3 Mechanistic evidence for the link between diabetes and cancer risk 
 
 Several mechanisms linking diabetes and cancer risk have been described including 
hyperinsulinemia, hyperglycemia and chronic inflammation (125). Hyperglycemia induces 
oxidative stress and activation of the renin-angiotensin system, and both mechanisms can 
produce dysregulation of cholesterol metabolism and endothelial dysfunction (131). Insulin 
can promote cancer through its direct effect on cell proliferation and survival, or indirectly 
by reducing the hepatic production of IGF binding protein with resultant increased 
circulating levels of IGF-1. In malignant cells, the A isoform of the insulin receptor is 
expressed predominantly and its activation can stimulate insulin-mediated mitogenesis 
(132). Additionally, many cancers express the IGF-1 receptor, which has shown to have a 
more mitogenic and transforming activity than the insulin receptor (125) . Finally, low-
grade chronic inflammation, a common feature in subjects with type 2 diabetes, can also 
induce cancer development through similar mechanisms as those explained in section 
1.3.4. 
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2  HYPOTHESIS AND OBJECTIVES 
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HYPOTHESIS 1: 
1.1 Low to moderate exposure to inorganic arsenic is associated with overall cancer 
mortality and with mortality from cancers of the lung, liver, prostate and kidney. 
HYPOTHESIS 2: 
2.1 Low to moderate exposure to cadmium is associated with overall cancer 
mortality, with mortality from tumors associated with tobacco smoke (including 
lung) and with mortality from cancers of the kidney and prostate. 
HYPOTHESIS 3: 
3.1 Measures of central adiposity (waist circumference and waist-to-hip-ratio), but 
not BMI are associated with an increased risk of breast cancer in premenopausal 
women. 
3.2 Measures of central (waist circumference and waist-to-hip-ratio) and general 
(BMI) adiposity are associated with an increased risk of breast cancer in 
postmenopausal women. 
3.3 Changes in weight since age 20 are associated with an increased risk of breast 
cancer both in pre and postmenopausal women. 
3.4 The effects of the studied anthropometric factors on cancer risk may differ by 
intrinsic subtypes. 
3.5 Measures of central (waist circumference and waist-to-hip-ratio) and general 
(BMI) adiposity are associated with an increased risk for advanced prostate cancers 
and a decreased risk for non-aggressive prostate tumors. 
HYPOTHESIS 4: 
4.1 Type-2 DM is associated with an increased risk of breast cancer in 
postmenopausal women. 
4.2 Type-2 DM is associated with a decreased risk of prostate cancer, and this 
decreased risk becomes stronger with longer diabetes duration. 
4.3 Metformin may reduce the risk of breast and prostate cancer, while insulin and 
insulin secretagogues may increase this risk. 
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OBJECTIVE 1: 
 
General objective: To evaluate the prospective association between exposure to heavy 
metals and cancer mortality in adults 45-75 years of age from 3 American Indian 
communities who participated in the Strong Heart Study from 1989-1991 through 2008. 
 
Specific objectives 
 
Objective 1.1: To evaluate the association of urinary inorganic arsenic with all 
cause and site-specific cancer mortality in Native Americans who  participated in 
the Strong Heart Study. 
 
Objective 1.2: To evaluate the association of urinary cadmium with all-cause and 
site-specific cancer mortality in Native Americans who participated in the Strong 
Heart Study. 
 
Objective 1.2.1: To assess the role of cadmium as a possible mediator in the 
association between tobacco smoke and cancer mortality. 
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OBJECTIVE 2: 
 
General objective: To estimate the effect of obesity, fat distribution and weight changes in 
adulthood over the risk of hormone-dependent tumors in adults 20-85 years of age who 
participated from 2008 to 2013 in a Spanish multicenter population-based case-control 
study (MCC-Spain). 
 
Specific objectives 
 
Objective 2.1: To study the association between several self-reported and 
measured anthropometric variables (age at maximum height, age at 
maximum weight, weight at ages 20 and 45, changes in weight since age 20, 
body-mass-index 1, waist circumference and waist-to-hip ratio) and the risk 
of breast cancer, overall and by intrinsic subtypes, in MCC-Spain. 
 
Objective 2.2: To study the association between several self-reported and 
measured anthropometric variables (age at maximum height, age at 
maximum weight, weight at ages 20 and 45, changes in weight since age 20, 
body-mass-index 1, waist circumference and waist-to-hip ratio) and the risk 
of prostate cancer, overall and Gleason score at diagnosis, in MCC-Spain. 
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OBJECTIVE 3: 
 
General objective: To evaluate the association between diabetes, diabetes treatment and 
diabetes duration with the risk of hormone-dependent tumors in adults 20-85 years of age 
who participated in a Spanish multicenter population-based case-control study (MCC-
Spain) from 2008 to 2013. 
 
Specific objectives 
 
Objective 3.1: To study the association between self-reported diabetes, 
diabetes duration and the risk of postmenopausal breast cancer, overall and 
by intrinsic subtypes, in MCC-Spain. 
 
Objective 3.2: To study the association between self-reported diabetes, 
diabetes duration and diabetes treatment and the risk of prostate cancer, 
overall and by Gleason score at diagnosis, in MCC-Spain. 
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3 METHODS 
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3.1 Methods for objective 1  
 
3.1.1 Study population 
 The Strong Heart Study (SHS) is the largest epidemiologic study of cardiovascular 
disease in American Indian populations ever undertaken. During 1989-1991, 4,549 men 
and women 45-75 years of age were recruited from 13 tribes and communities in three 
geographic regions: an area near Phoenix (Arizona), the southwestern area of Oklahoma, 
and western and central North and South Dakota.  
 
Figure 3.1: Map of the Strong Heart Study Communities. 
 
 The aim was to recruit approximately 1,500 participants per region. In Arizona and 
Oklahoma every eligible person was invited; in North/South Dakota a cluster sampling 
technique was used (133). Overall, the baseline participation rate was 62%. The Strong 
Heart Study protocol and consent form were approved by the Institutional Indian Health 
Service Review Boards and by the participating Indian communities. Informed consent 
was obtained from all participants. 
 The Strong Heart Study was initially designed to study the prevalence of known or 
suspected cardiovascular disease risk factors in American Indians, and to assess their 
influence on cardiovascular morbidity and mortality (http://strongheart.ouhsc.edu/). 
However, the long follow-up of Strong Heart Study participants has allowed us to 
secondary evaluate the influence of some of this risk factors on cancer mortality.  
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3.1.1.1 Study sample 
 From the initial population, we excluded participants with insufficient urine for 
metal analyses and participants with missing values in potential important confounders, 
leaving 3,935 participants for arsenic and 3,792 for cadmium analyses. The smaller sample 
size in the case of cadmium is explained by the exclusion of participants with no 
information on cigarette pack-years, as tobacco smoking is one of the most relevant 
potential confounders in the association between cadmium and cancer risk. In the case of 
arsenic, adjustment for cigarette pack-years was only performed as a sensitivity analyses, 
and so individuals with no information on this variable were included in the main results. 
   
3.1.2 Exposure assessment 
  Spot urine samples were collected in polypropylene tubes, frozen within 1 to 2 
hours of collection, shipped buried in dry ice and stored at -70°C in the Penn Medical 
Laboratory, MedStar Research Institute, Washington, DC for up to 18 years. The freezers 
have been operating under a strict quality control system to guarantee secure sample 
storage. For analysis, urine samples were thawed. From each urine sample, up to 1.5 mL 
for arsenic and 1.0 mL for cadmium determinations were transferred to a small vial, 
transported on dry ice to the Trace Element Laboratory at Graz University, Austria and 
stored at -80°C. 
 Inorganic arsenic (arsenite, arsenate), monomethylarsonate (MMA), 
dimethylarsinate (DMA), and arsenobetaine plus other arsenic cations were measured 
using anion-exchange high-performance liquid chromatography (Agilent 1100 HPLC, 
Agilent Technologies, Waldbronn, Germany) coupled with inductively coupled plasma 
mass spectrometry (Agilent 7700x ICPMS). The limits of detection were 0.1 µg/L for total 
arsine and 0.5 µg/L for arsenite, arsenate, methylarsonate (MMA) and dimethylarsinate 
(DMA). The percentages of participants with concentrations below the limit of detection 
were 5.3% for inorganic arsenic, 0.7 % for MMA, 0.03 % for DMA and 2.1% for 
arsenobetaine plus other cations. For participants with concentrations below the limit of 
detection we divided the corresponding limit of detection by the square root of two. The 
inter-assay coefficients of variation were 6.0% for inorganic arsenic, 6.5% for MMA, 5.9% 
for DMA and 6.5% for arsenobetaine plus other cations. Arsenobetaine concentrations 
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were very low (median 0.76 µg/L, interquartile range 0.47-1.70 µg/L), confirming that 
seafood intake is rare in the Strong Heart Study population. 
 Urine cadmium concentrations were measured using inductively coupled plasma-
mass spectrometry (ICPMS). The limit of detection for urine cadmium was 0.015µg/L with 
only one participant having values below this limit. The inter-assay coefficient of variation 
was 8.7%. Urine cadmium concentrations were corrected for molybdenum oxide 
interference using the formula [Cd]corr = [Cd]-0.0016*[Mo] (134). 
 
3.1.3 Data collection and variables definition 
 Study visits were performed by trained and certified examiners following a 
standard protocol (133), and included a questionnaire, a physical examination and 
biospecimen collection (blood, urine). Information on sociodemographic factors (age, sex, 
study region, education), smoking status, alcohol use, reproductive factors in women 
(menopausal status, parity) and medical history was obtained from the baseline SHS 
questionnaire (133). Height and weight were measured and body mass index was 
calculated as weight in kg divided by height in meters squared. Hypertension was defined 
as mean systolic blood pressure ≥140 mm Hg, mean diastolic blood pressure ≥90 mm Hg, 
or antihypertensive medication use. Plasma creatinine was measured by an alkaline-picrate 
rate method. Estimated glomerular filtration rate (eGFR) was calculated from calibrated 
creatinine, age and sex using the Modification of Diet in Renal Disease Study formula 
without an ethnicity factor. Diabetes, a major public health problem in the study 
communities, was defined as fasting plasma glucose ≥126 mg/dL, 2-h post-load plasma 
glucose ≥200 mg/dL, hemoglobin A1c ≥6.5%, or use of insulin or oral hypoglycemic 
agents. Methods to measure fasting glucose, 75-g oral glucose tolerance test, and 
hemoglobin A1c have been described elsewhere (133). 
 Urine creatinine was measured at the laboratory of the National Institute of 
Diabetes and Digestive and Kidney Diseases Epidemiology and Clinical Research Branch 
(Phoenix, AZ, USA) by an automated alkaline picrate methodology (133). To account for 
urine dilution in spot urine samples, we divided urine arsenic by urine creatinine and 
expressed the concentrations of total urine arsenic and its species as micrograms per gram 
creatinine.   
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3.1.4 Cancer mortality follow-up 
 Follow-up for mortality was complete for 99.8% of the study population (135). 
Death certificates were obtained from the State Departments of Health. If the death 
certificate indicated that an autopsy had been performed, the medical examiner´s report 
was obtained (133). Death certificate codes were recorded by a single nosologist according 
to the International Classification of Diseases, 9th Revision (ICD-9) (136). Malignant 
neoplasm include ICD-9 codes 140 to 208. In addition to total cancer, we evaluated the 
following specific cancers: esophagus and stomach (ICD-9 150-151), colon and rectum 
(ICD-9 153-154), liver and intra-hepatic bile ducts (ICD-9 155) gallbladder and extra-
hepatic bile ducts (ICD-9 156), pancreas (ICD-9 157), bronchus and lung (ICD-9 162.2-
162.9) (referred from now on as lung cancer), breast (ICD-9 174), prostate (ICD-9 185), 
kidney (ICD-9 189.0) and lymphatic and hematopoietic tissue (ICD-9 200-208). Skin and 
bladder cancers were not evaluated as the corresponding number of deaths was very small 
(2 and 1, respectively).  
 For cadmium analyses, we grouped cancer with sufficient evidence for tobacco 
smoking according to the IARC (IARC 2012): Lip, oral cavity and pharynx (ICD-9 140-
149), esophagus (150), stomach (151), colon and rectum (ICD-9 153-154), liver (155), 
pancreas (157), larynx (161), trachea, bronchus and lung (162), cervix (180), bladder 
(188), kidney (189), myeloid leukemia (205).  
 Time to event was calculated from the date of baseline examination to the date of 
death or to December 31, 2008 whichever occurred first. The mean follow-up time among 
participants who did not have a cancer death was 14.6 for participants with arsenic and 
16.2 for participants with cadmium determinations at baseline. 
 
3.1.5 Statistical methods 
3.1.5.1 Specific methods for objective 1.1 
 We used the sum of inorganic (arsenite and arsenate) and methylated (MMA and 
DMA) arsenic corrected by urine creatinine as the biomarker of exposure to inorganic 
arsenic. Seafood intake in the SHS population was rare (137), as confirmed by very low 
concentrations of arsenobetaine (median 0.76 µg/L, interquartile range 0.47 and 1.70 
µg/L), thus allowing us to use the sum of inorganic and methylated arsenic species as a 
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biomarker of inorganic arsenic exposure. Urine arsenic concentrations were markedly 
right-skewed and were log-transformed for statistical analyses.  
 The prospective association between the creatinine-corrected sum of inorganic and 
methylated arsenic and cancer mortality (overall and site-specific) was assessed using Cox-
proportional hazards models with age as time scale and individual starting follow-up times 
(age at baseline examination) treated as staggered entries. This approach effectively adjusts 
for age. The assumption of hazards proportionality was evaluated based on the smoothed 
association between age and scaled Schoenfeld residuals (138), with no major departures 
from proportionality. In order to control for region, the non-parametric underlying baseline 
hazards were allowed to differ by study region using the strata command in Stata. We 
modeled arsenic in 3 ways: (1) tertiles; (2) 80
th
 vs. 20
th
 percentiles of log-transformed 
arsenic; and (3) restricted cubic splines with knots at the 10
th
 (3.80 µg/g creatinine), 50
th
 
(9.68 µg/g) and 90
th
 (24.0 µg/g) percentiles to evaluate potential non-linear relationships. 
P-values for linear trend were obtained from Wald tests by introducing log-arsenic 
concentrations as a continuous variable. Departures from linearity in the restricted cubic 
spline models were evaluated using the Wald test.  
 All Cox-proportional hazards models initially accounted for region (stratification 
factor) and age. In addition, we further adjusted for sex, education (<high school, some 
high school, ≥high school), smoking status (never, former, current), drinking status (never, 
former, current) and BMI. For breast cancer, models were further adjusted for menopausal 
status and parity. For kidney cancer, we further adjusted for hypertension (no, yes) and 
reduced estimated glomerular filtration rate (<60, ≥60 ml/min/1.72m2) (139). 
 To evaluate the consistency of the findings across participant subgroups, 
exploratory analyses for overall cancer mortality included interaction terms for log-
transformed sum of inorganic and methylated arsenic concentrations with indicator 
variables for subgroups defined by age (<55, 55-64, >64 y), sex (men, women), smoking 
status (never, former, current), diabetes (yes/no), %DMA (tertiles) and %MMA (tertiles) in 
separate models. Subgroup analyses were not conducted for specific cancer mortality 
because the number of deaths was too small. 
 We performed several sensitivity analyses. First, in participants with cigarette pack-
year information (N=3,789), we further adjusted for cigarette pack-years. Second, to 
account for death by causes other than cancer, we estimated proportional hazard regression 
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models for competing risks according to the method of Fine and Gray (140) using stcrreg 
command in Stata. Third, to reduce the possibility that prevalent cancers at baseline could 
affect urine arsenic concentrations we repeated the analyses excluding participants during 
the first 2 years or the first 5 years of follow-up. Fourth, to evaluate the stability of the 
effect along time we conducted separate analyses for the first and second decades of 
follow-up. Fifth, to confirm that the findings were not affected by using age as the time 
scale, we fitted models using calendar time as the time scale and adjusted by age, and 
tested if the proportional hazard assumption was fulfilled for arsenic. The results of these 
sensitivity analyses were similar to those of the main analyses (not shown). Finally, we 
used the following two alternative strategies to account for urine dilution: (1) adjusting for 
log-transformed urine creatinine in the regression models instead of dividing urine arsenic 
by urine creatinine concentrations; (2) adjusting urine arsenic concentrations to the overall 
mean specific gravity in the study population of 1.019 (141). This last analysis was 
restricted to participants without albuminuria and diabetes because specific gravity is 
inadequate to adjust for dilution if albumin or glucose are present in urine (142;143).  
 
3.1.5.2 Specific methods for objective 1.2  
 Urine cadmium concentrations were also right-skewed and log-transformed for 
statistical analyses. To account for urine dilution in spot urine samples, we divided 
cadmium by urine creatinine. 
 Similarly to the analyses for arsenic, the prospective association between 
creatinine-corrrected cadmium concentrations and cancer mortality was assessed using 
Cox-proportional hazards models with age as time scale and individual starting follow-up 
times treated as staggered entries. Cadmium was also modeled in 3 different ways: (1) 
tertiles; (2) 80
th
 vs. 20
th
 percentiles of log-transformed cadmium; and (3) restricted cubic 
splines with knots at the 10
th
 (0.40 µg/g creatinine), 50
th
 (0.93 µg/g creatinine) and 90
th 
(2.15 µg/g creatinine). For pancreas cancer, there was only 1 case in the first cadmium 
tertile and for this reason we combined the first and second tertiles.  
 All Cox-proportional hazard models initially accounted for age and region. A 
second model further adjusted for sex, BMI, smoking status and cigarette pack-years. For 
kidney cancer mortality we also adjusted for hypertension and reduced estimated 
glomerular filtration rate, and for breast cancer mortality, for parity. In addition, we 
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adjusted models for postmenopausal status in women, education and drinking status added 
one by one, with similar results (data not shown). 
 To evaluate the consistency of our findings across participants’ subgroups, 
exploratory analyses for overall cancer mortality and for smoking-related cancer mortality 
included interaction terms for log-transformed cadmium with indicator variables for 
subgroups defined by age, sex, menopausal status, smoking status, pack-years, BMI and 
urine arsenic concentrations in separate models. We could not conduct interaction analyses 
for specific cancers due to the relatively small number of events. 
 Finally, as in the case of arsenic, sensitivity analyses included accounting for 
competing risks using Stata stcrreg command, excluding participants during the first 2 or 5 
years of follow-up, conducting separate analyses for the first and second decades of 
follow-up and using alternative strategies to account for urine dilution.  
 
3.1.5.3 Specific methods for objective 1.2.1  
 
 To assess the role of cadmium as a possible mediator in the association between 
tobacco smoke and cancer mortality we calculated the proportion of additional cases of 
lung cancer due to tobacco smoking that could be attributed to cadmium exposure, using 
the method proposed by Lange et al. (144), with bootstrap confidence intervals estimated 
as bias-corrected and accelerated percentile intervals. According to this method, we first 
calculated the direct effect of smoking, as measured by pack-years, on cancer (direct 
pathway) using the Aalen additive hazard model. Then, we calculated the indirect effect 
using 2 models: 1) a linear regression with cadmium as the dependent variable and number 
of pack-years as the independent variable and 2) the Aalen additive hazard model for 
cadmium adjusted for pack-years. The proportion of lung cancer mortality associated with 
a 10 pack-year increase that can be attributed to cadmium exposure, as measured in urine, 
was calculated as the ratio of the indirect to the total effect. 
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3.2 Methods for objectives 2 and 3 
 
3.2.1 Study population 
 MCC-Spain is a population-based case-control study focusing in frequent tumors 
and/or tumors with peculiar epidemiological characteristics in Spain (http://mccspain.org/). 
Histologically confirmed cases of breast (ICD-10: C50, D05.1, D05.7), prostate (ICD-10: 
C61, D07.5), colon or rectum (ICD-10: C18, C19, C20, D01.0, D01.1, D01.2), stomach 
(ICD-10: C16, D00.2), oesophagus (ICD-10: C15.5), or chronic lymphocytic leukaemia 
and small lymphocytic lymphoma (ICD-10: C91.1) were recruited from 22 Spanish public 
hospitals between 2008 and 2013. Cases were identified through the medical registries of 
the participating hospitals. All cases were incident and were excluded if they had a 
previous diagnosis of cancer in the same location under study. Inclusion criteria required 
that cases had lived for at least 6 months in the one of the study areas and were between 
20-85 years of age. 
 
Figure 3.2: Map of the recruiting centers in MCC-Spain. 
 
 Population-based controls were randomly selected from lists of primary care health 
centres within the catchment areas of the hospitals where cases were recruited and 
contacted by telephone. Controls were frequency-matched to the cases, taking into account 
age, sex and region. Exclusions were made if patients had any physical or mental disorder 
that could impede their participation in the study. 
 Response rates were 53% for healthy controls, 71% for breast cancer cases and 
72% for prostate cancer cases. There were no differences in the main socio-demographic 
variables among those who participated and those who refused to participate. All 
participants who agreed to participate signed an informed consent and the study was 
formally approved by the corresponding Ethics Committee of each area. The MCC-Spain 
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study also followed the declaration of Helsinki and the Spanish Personal Data Protection 
Act of 1999 (Ley Organica 15/1999 de 13 de Diciembre).  
 
3.2.1.1 Study sample 
 A total of 1743 breast cancer cases with 1880 matched controls, and 1113 prostate 
cancer cases with 1460 controls were recruited. The study design intended that all 
interviewers would collect data from cases and control, but in a small number of 
participants this was not possible. In addition, not all interviewers registered information 
for all types of tumors.  
 For the analyses on anthropometric factors and cancer risk, we excluded those 
participants whose interviewers had only interviewed cases or controls (Nbreast cancer 
cases=104; Nbreast cancer controls=168; Nprostate cancer =141; Nprostate controls =140). The reason to 
exclude these participants is that even though a standardized protocol was used to measure 
the waist and hip circumferences, the measurement process includes an additional source 
of variability that we wanted to control in the analyses by including the interviewer as a 
random effect term. Pregnant women (N=15) and participants with missing values in BMI 
or other important confounders were also excluded from the analyses, leading to a final 
sample of 1487 breast cancer cases with 1500 controls; and 1018 prostate cancer cases 
with 1327 controls.  
 For the analyses on diabetes and cancer risk, we decided not to include 
premenopausal women because the prevalence of diabetes was very low in this specific 
subgroup. From the initial 1035 cases of postmenopausal breast cancer with 1252 controls, 
and 1113 prostate cancer cases with 1460 controls, we excluded those participants with no 
information on diabetes, diabetes duration or diabetes treatment (Nbreast cancer cases=20; Nbreast 
cancer controls=23; Nprostate cancer cases=21; Nprostate cancer controls= 51), as well as those with no 
information in BMI (Nbreast cancer cases=67; Nbreast cancer controls=110; Nprostate cancer cases=17; 
Nprostate cancer controls= 30) or other important confounders (Nbreast cancer cases=17; Nbreast cancer 
controls=9; Nprostate cancer cases=5; Nprostate cancer controls=3). However, in a sensitivity analyses, we 
also included participants with missing values in BMI and imputed their BMI values to 
check the consistency of the results. In order to reduce the probability of including type-1 
diabetic individuals as exposed, we also excluded participants who had been diagnosed of 
diabetes before the age of 45 (Nbreast cancer cases=8; Nbreast cancer controls=11; Nprostate cancer cases=10; 
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Nprostate cancer controls=21). Finally, to allow for a minimum latency period and to avoid that 
the clinical conditions that lead to diabetes and cancer diagnosis could overlap, we also 
excluded participants diagnosed of diabetes ≤ 1 year before the diagnosis of cancer (Nbreast 
cancer cases=7; Nbreast cancer controls=5; Nprostate cancer cases=6; Nprostate cancer controls= 14), leading to a 
final sample of 916 cases and 1094 controls of postmenopausal breast cancer and 1054 
cases and 1341 controls of prostate cancer.  
 
3.2.2 Data collection and variables definition 
 Both cases and controls were interviewed by purposed trained personal, who 
collected data on socio-demographic factors, health behaviors (such as smoking, dietary 
patterns, physical activity and screening attendance), gynecologic and obstetric history in 
female participants, anthropometric factors (age at maximum height; weight at age 20 and 
age 45; age at maximum weight; weight and height one year prior to the interview), family 
history of cancer, pre-existing medical conditions (including self-reported diabetes and 
self-reported age at diagnosis) and treatments received (comprising starting age and current 
dose). At the end of the questionnaire, interviewers were asked to classify the overall 
quality of the participant’s responses as “fair”, “good” or “excellent”.  
 Waist and hip circumferences were measured twice by the interviewer. The waist 
circumference was measured at the midpoint between the lowest rib and the iliac crest, and 
the hip circumference around the widest portion of the buttocks. In accordance with 
standardized protocols, if the first two measures were dissimilar, a third measurement was 
taken.  
 Body mass index one year prior to the interview was calculated as the ratio of 
weight in kilograms to the square of height in meters, and the waist-to-hip ratio computed 
as the ratio of the circumference of the waist to that of the hips in centimeters. Adult 
weight gain was defined as the number of kg of difference between self-reported weight at 
age 20 and self-reported weight one year before the study interview. 
 Time since diagnosis of diabetes was computed as the age at interview minus the 
age at fist diagnosis of diabetes. Because the clinical conditions that lead to diabetes and 
cancer diagnosis may overlap, we required that diabetic participants had been diagnosed of 
diabetes at least 1 year before the interview. In the same way, to allow for a minimum 
latency period, all potential confounders that could be modified by the disease (BMI, 
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tobacco consumption, calorie intake and physical exercise) were censored to one year prior 
to the interview.  
 Self-reported diabetic drugs were classified according to the Anatomical 
Therapeutic Chemical Classification System of the WHO. Because the number of 
participants per subgroup was small, only two main categories are considered for this 
report: A10A (insulin and analogues) and A10B (blood glucose lowering drugs, excluding 
insulin). In accordance to this, diabetic participants have been classified into three different 
groups regarding the last treatment regimen they had received for at least one year: 1) 
diabetics under conservative therapy, 2) those treated with blood glucose lowering drugs 
and 3) diabetics treated with insulin regardless of their use of blood glucose lowering 
drugs. The duration of each drug use was calculated as the age at the end of treatment (or 
at the time of interview in the case of current treatments) minus the age at the beginning of 
treatment. 
 
3.2.3 Tumor classification 
 Trained personnel reviewed all pathologic records and registered information 
regarding histological type and receptor status in breast cancer cases, and Gleason score in 
prostate tumors. Breast cancers were divided into three groups according to the 
presence/absence of the estrogen receptor (ER), progesterone receptor (PR) or the human 
epidermal growth factor receptor (HER2) as follows: 1) Hormone receptor positive tumors 
(ER+ or PR+ with HER2-); 2) HER2+ tumors (independent of ER or PR) and 3) triple 
negative tumors (ER-, PR- and HER2-). Prostate cancers were classified according to their 
Gleason score into high- (Gleason >6) and low-grade (Gleason ≤6). 
 
3.2.4 Statistical methods 
3.2.4.1 Specific methods for objectives 2.1 and 2.2 
 Descriptive statistics of participant’s characteristics were calculated for both cases 
and controls. Categorical variables were described using percentages, and continuous 
variables using means and standard errors. Intra-observer reproducibility of measurements 
was studied by Pearson's concordance correlation coefficient. The association of the main 
explanatory variables (age at maximum height; weight at ages 20 and 45; age at maximum 
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weight; changes in weight since age 20; BMI; WC and WHR ratios) with the risk of breast 
or prostate tumors, was evaluated using logistic mixed models, including the interviewer as 
a random effect term, as implemented in Stata´s gllamm command. For each explanatory 
variable, two different regression models were estimated. Model 1 accounted for age, study 
level, recruitment area and family history of the studied cancer (breast or prostate). 
Additionally, when breast cancer was the tumor of interest, model 1 adjusted for 
menopausal status, age of menarche, age at first birth and existence of previous biopsies. 
Model 2 further adjusted for BMI. In women, both models 1 and 2 were also separately 
fitted stratified by menopausal status. 
 Restricted cubic splines with knots at the 10
th
, 50
th
 and 90
th
 percentiles were used to 
explore the shape of the dose-response curves for the different variables of interest. These 
spline models include all the confounders considered in “model 2”. 
 Finally, in order to explore whether the effect of our anthropometric variables 
differed by cancer subtype, multinomial logistic models were fitted, considering in each 
case the aforementioned subtypes of breast and prostate cancer, and adjusting again for the 
confounders included in “model 2”. Heterogeneity of effects was tested using a Wald test 
comparing the slope coefficients obtained for the different cancer subtypes. 
 To evaluate the consistency of our findings, we performed several sensitivity 
analyses. First, we repeated all models after excluding those participants whose interviews 
were not classified as “good” or “excellent” by their interviewers (N=184 for BC analyses; 
N=38 for PC analyses). Second, we further adjusted the models for diabetic status (yes/no) 
when this information was available (Nwomen=2949; Nmen=2178). Third, for breast cancer 
we repeated the analyses including only those women who had not received hormonal 
replacement therapy (N=2517). Fourth, when weight gain was the main variable of interest 
we also adjusted the models for the reported weight at age 20. Finally, we repeated all 
models stratified by BMI (normoweight/overweight or obese). 
 
3.2.4.2 Specific methods for objectives 3.1 and 3.2 
 Similarly to what is explained for objectives 2.1 and 2.2, descriptive statistics of 
participant characteristics were calculated for both cases and controls by diabetes status. 
To evaluate the association between diabetic status (yes/no) and cancer risk, we fitted 
multivariate logistic mixed models, including the study region as a random effect term, and 
53 
 
adjusting for age, study level, BMI and family history of the studied cancer. When 
postmenopausal breast cancer was the outcome, we further adjusted the models for age at 
menarche, age at first birth and existence of previous biopsies.  
 To study whether diabetes treatment could be associated with cancer incidence we 
followed two different strategies. First, we evaluated the risk of cancer associated with 
different treatment regimens (conservative, oral medication, insulin +/- oral medication) 
using the non-diabetic population as the reference category. Then we quantified the 
potential association between duration of use of specific antidiabetic drugs (i.e. metformin, 
sulfonylurea) and cancer risk in the diabetic population. For both strategies, we used 
multivariate logistic mixed models with study region as a random effect term, and similar 
adjustment variables as those described for models on diabetic status.  
 The association between diabetes duration and cancer risk was assessed again using 
multivariate logistic mixed models with the same explanatory variables as those previously 
specified. In these models, diabetes duration was introduced either as a continuous 
variable, or, in order to evaluate potential nonlinear relationships, as restricted cubic 
splines with knots at the 10
th
, 50
th
 and 90
th
 percentiles of its distribution.  
 Again, we explored if the effects of diabetes, diabetes treatment or diabetes 
duration could differ by cancer subtype, fitting multinomial logistic models. Heterogeneity 
of effects was also tested using a Wald test.  
 As sensitivity analyses we repeated all models after excluding those participants 
whose interviews has not been classified as “good” or “excellent” by their interviewers. 
We also adjusted for tobacco consumption, calorie intake and physical exercise when this 
information was available (Nwomen=1732; Nmen=2030), and we repeated the models 
including participants with missing values in BMI (N=177 women and N=47 men) after 
performing multiple imputation on this variable. We also explored if the effect of diabetes 
or diabetes treatment varied across categories of BMI by introducing an interaction term 
between the independent variables and BMI (normoweight/overweight or obese) in the 
models. Finally, in order to evaluate potential differences in risk associated with frequency 
of medical visits, we also stratified our results by “screening habits during the last 5 years”. 
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4 RESULTS 
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4.1 Results for objective 1 
 
4.1.1 Characteristics of the sample  
 The mean (± SD) age at study entry was 56 ± 8 years, and 41% of the studied 
individuals were males. The Strong Heart Study participants had a high prevalence of 
diabetes (50 %), obesity (50%) and alcohol consumption (42%). The prevalence of 
cigarette smoking was also high (67% were current or former smokers), although the 
amount of smoking was relatively low (mean pack-years =16.3).  
 A total of 225 women and 160 men died from cancer during the studied period. The 
most common cancer sites were lung and breast in women, and lung and prostate in men. 
Older participants, participants living in North and South Dakota, participants with lower 
education, current smokers and never drinkers had higher cancer mortality.  
 The median (IQR) concentration for the sum of inorganic and methylated arsenic at 
baseline was 9.7 (5.8-15.6) µg/g creatinine [10.4 (6.12-18.4) µg/L]. Participants living in 
Arizona and North and South Dakota, participants who had a lower education, current 
drinkers, and those with lower body mass index and diabetes had higher urine arsenic 
concentrations (Table 4.1). The median percentage of arsenic species was 8% for inorganic 
arsenic, 14% for MMA and 78% for DMA. 
 The median (IQR) concentration of cadmium at baseline was 0.93 (0.61-1.46) µg/g 
creatinine [1.02 (0.60-1.70) µg/L], with higher levels observed in North and South Dakota 
(Table 4.2). Urine cadmium concentrations were higher in women, older participants, 
participants with lower education, current smokers and participants with lower BMI.   
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Table 4.1 Median (IQR) for the sum of inorganic and methylated arsenic concentrations 
(µg/g creatinine) by participant characteristics 
Variable Category N Median (IQR) p-value* 
Overall 
 
3,935 9.7 (5.8-15.6) 
 
Age <55 years 1,947 9.7 (5.9-15.7) 
 
 55-64 1,292 9.6 (5.7-15.4) 
 
 >65 696 9.7 (5.6-15.8) 
0.28 
Sex Male 1,603 8.8 (5.1-14.3) 
 
 Female 2,332 10.4 (6.2-16.6) 
<0.001 
Region Arizona 1,314 14.3 (9.9-20.8) 
 
 Oklahoma 1,318 5.6 (3.8-8.2) 
 
 Dakota 1,303 10.6 (6.9-15.8) 
<0.001 
Education  No high school 868 13.1 (8.9-20.3) 
 
 Some high school 992 10.1 (5.9-16.6) 
 
 Completed high school 2,075 8.0 (5.0-13.2) 
<0.001 
Smoking  Never 1,284 10.1 (6.0-16.5) 
 
 
Former 1,338 9.2 (5.6-15.0) 
 
Current 1,313 9.7 (5.8-15.4) 
0.01 
Alcohol  Never 636 9.2 (5.5-15.5) 
 
 Former 1,650 8.7 (5.3-14.4) 
 
 Current 1,649 10.8 (6.4-17.1) 
<0.001 
BMI <25 kg/m
2
 610 10.7 (5.8-17.6) 
 
 25-30 1,324 9.6 (5.6-15.7) 
 
 >30 2,001 9.5 (5.9-15.0) 
0.02 
Diabetes No 1,986 8.4 (5.1-13.6) 
 
 Yes 1,939 11.0 (6.6-18.0) 
<0.001 
                *p-value from Kruskall-Wallis exact test 
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Table 4.2 Median (IQR) urine cadmium concentrations (µg/g creatinine) by participant 
characteristics 
Variable Category N Median (IQR) p-value* 
Overall  3792 0.93 (0.61-1.46)  
Age <55 1883 0.88 (0.57-1.35)  
 55-64 1166 1.00 (0.65-1.56)  
 ≥64 743 0.98 (0.63-1.53) <0.001 
Sex Male 1538 0.71 (0.46-1.08)  
 Female 2254 1.11 (0.74-1.71) <0.001 
Post-menopausal women Yes 521 1.03 (0.70-1.51)  
 No 1733 1.13 (0.75-1.74) 0.001 
Region Arizona 1268 0.82 (0.55-1.22)  
 Oklahoma 1252 0.87 (0.57-1.35)  
 Dakota 1272 1.13 (0.75-1.80) <0.001 
Education  < High school 834 1.01 (0.66-1.57)  
 High school 965 1.01 (0.65-1.59)  
 >High school 1993 0.88 (0.57-1.34) <0.001 
Smoking status Never 1284 0.88 (0.57-1.36)  
 Former  1212 0.79 (0.53-1.22)  
 Current 1296 1.14 (0.74-1.73) <0.001 
Cigarette pack-years 0 1284 0.88 (0.57-1.36)  
 1-4 931 0.84 (0.54-1.29)  
 5-19  748 0.93 (0.62-1.44)  
 >= 20  829 1.14 (0.76-1.72) <0.001 
Alcohol Never 621 1.03 (0.67-1.59)  
 Former 1583 0.91 (0.60-1.46)  
 Current 1588 0.91 (0.59-1.39) <0.001 
BMI, Kg/m
2
 <25 591 1.17 (0.75-1.84)  
 25-30 1276 0.96 (0.61-1.50)  
 >=30 1925 0.86 (0.57-1.30) <0.001 
* P-value from Kruskall-Wallis exact test 
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4.1.2 Association between arsenic exposure and cancer mortality 
 After multivariate adjustment for age, sex, education, BMI, smoking status and 
drinking status, the hazard ratio (95% confidence interval) for overall cancer mortality 
comparing the 80
th
 vs. the 20
th
 percentile of the sum of inorganic and methylated arsenic 
concentrations in urine was 1.14 (0.92-1.41) (Table 4.3). The corresponding hazard ratios 
for cancers of the lung, liver, prostate and kidney were 1.56 (1.02-2.39), 1.34 (0.66, 2.72), 
3.30 (1.28-8.48) and 0.44 (0.14, 1.14), respectively. For pancreatic cancer, the 
corresponding hazard ratio was 2.46 (1.09-5.58) and for lymphatic and hematopoietic 
cancers it was 0.46 (0.22-0.96). Arsenic was not associated with cancers of the esophagus 
and stomach, colon and rectum, or breast. The linear trend for increased mortality with 
increasing arsenic levels was statistically significant for lung cancer (p=0.04), prostate 
cancer (p=0.01) and pancreatic cancer (p=0.03). When modeling the dose-response 
relationship using restricted cubic splines, we observed no significant departures from 
linearity (Figure 4.1).  
 In subgroup analyses by participant characteristics, the fully-adjusted hazard ratio 
for overall cancer mortality comparing the 80th vs. 20th percentile of arsenic was 
consistent for most participant subgroups except diabetes at baseline (p for 
interaction=0.07). No interaction or consistent pattern was observed between urine arsenic 
concentrations and relative proportions of urine arsenic metabolites in urine (%MMA or 
%DMA) for overall cancer (Figure 4.2).  
 In sensitivity analyses adjusting for log-transformed urine creatinine, the hazard 
ratio for overall cancer mortality comparing the 80th vs. 20th percentile of arsenic was 
1.12 (0.88-1.42) and for lung cancer mortality it was 1.53 (0.94-2.48). Among participants 
without diabetes or albuminuria (N=1,765, 166 overall cancers, 48 lung cancers), the 
corresponding hazard ratios for overall and lung cancer mortality were 1.29 (0.96-1.73) 
and 1.35 (0.80-2.27) when adjusting for overall mean specific gravity. Finally, when 
excluding deaths coded as “malignant neoplasms of other or unspecified sites” (n=26) from 
the analysis for overall cancer mortality, the results remained similar, and the observed HR 
(95%CI) comparing the 80
th
 vs 20
th
 percentiles of arsenic distribution was 1.16 (0.93-1.44). 
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 Table 4.3. Hazard ratios (95% CI) for cancer mortality by urine arsenic concentrations 
 Sum inorganic and methylated arsenic tertiles  80
th
 vs 20
th
  
 <6.91 µg/g 6.91-13.32µg/g >13.32 µg/g percentiles* p-trend** 
Overall cancer (ICD-9 140 to 208) 
Cases / Non Cases 121/1,198 135/1,181 130/1,170 386/3,549  
Model 1 1 (Referent) 1.17 (0.90-1.52) 1.27 (0.96-1.70) 1.16 (0.94-1.42) 0.16 
Model 2 1 (Referent) 1.17 (0.90-1.53) 1.23 (0.92-1.65) 1.14 (0.92-1.41) 0.24 
Trachea, bronchus, and lung (ICD-9 162) 
Cases / Non Cases 27/1,292 20/1,296 31/1,269 78/3,857  
Model 1 1 (Referent) 0.89 (0.49-1.62) 1.95 (1.09-3.49) 1.59 (1.05-2.42) 0.03 
Model 2 1 (Referent) 0.94 (0.51-1.72) 1.82 (1.00-3.32) 1.56 (1.02-2.39) 0.04 
Liver, gallbladder and bile ducts (ICD-9 155-156)  
Cases / Non Cases 8/1311 13/1303 13/1287 34/3901  
Model 1 1 (Referent) 1.51 (0.59-3.88) 1.56 (0.56-4.32) 1.50 (0.76-2.97) 0.24 
Model 2 1 (Referent) 1.38 (0.53-3.62) 1.36 (0.47-3.95) 1.34 (0.66-2.72) 0.41 
 
Prostate (ICD-9 185)  
Cases / Non Cases 6/605 5/526 7/454 18/1,585 
 Model 1 1 (Referent) 1.25 (0.37-4.26) 2.90 (0.85-9.92) 1.91 (0.82-4.41) 0.13 
Model 2 1 (Referent) 1.55 (0.45-5.33) 4.58 (1.31-16.6) 3.30 (1.28-8.48) 0.01 
Kidney (ICD-9 189.0) † 
Cases / Non Cases 9/1,310 9/1,307 8/1,292 26/3,909 
 Model 1 1 (Referent) 0.68 (0.25-1.86) 0.50 (0.15-1.42) 0.69 (0.25-1.90) 0.28 
Model 2 1 (Referent) 0.69 (0.25-1.90) 0.44 (0.14-1.40) 0.44 (0.14-1.40) 0.36 
Esophagus and Stomach Cancer (ICD-9 150-151) 
Cases / Non Cases 8/1,311 8/1,308 8/1,292 24/3,911  
Model 1 1 (Referent) 1.19 (0.42-3.39) 1.33 (0.41-4.29) 0.94 (0.40-2.24) 0.89 
Model 2 1 (Referent) 1.33 (0.46-3.84) 1.57 (0.47-5.26) 1.09 (0.45-2.66) 0.85 
Pancreas (ICD-9 157) 
Cases / Non Cases 7/1,312 7/1,309 11/1,289 25/3,910  
Model 1 1 (Referent) 1.04 (0.34-3.19) 2.14 (0.67-6.82) 2.26 (1.04-4.88) 0.04 
Model 2 1 (Referent) 1.04 (0.33-3.29) 2.14 (0.67-6.82) 2.46 (1.09-5.58) 0.03 
Colon and rectal cancer (ICD-9 153-154) 
Cases / Non Cases 12/1,307 14/1,302 6/1,294 32/3,903 
 Model 1 1 (Referent) 1.46 (0.65-3.29) 0.87 (0.30-2.57) 0.83 (0.40-2.24) 0.62 
Model 2 1 (Referent) 1.41 (0.62-3.21) 0.82 (0.27-2.48) 0.78 (0.36-1.67) 0.52 
Breast (ICD-9 174) †† 
Cases / Non Cases 7/701 13/772 6/833 26/2,306  
Model 1 1 (Referent) 1.79 (0.67-4.74) 0.90 (0.27-3.07) 0.84 (0.37-1.93) 0.99 
Model 2 1 (Referent) 1.92 (0.71-5.15) 0.96 (0.28-3.22) 1.00 (0.44-2.28) 0.69 
Lymphatic and hematopoietic tissue (ICD-9 200–208) 
Cases / Non Cases 11/1,308 20/1,296 9/1,291 40/3,895 
 Model 1 1 (Referent) 1.63 (0.74-3.61) 0.69(0.26-1.87) 0.59 (0.29-1.17) 0.13 
Model 2 1 (Referent) 1.44 (0.64-3.25) 0.57 (0.21-1.58) 0.46 (0.22-0.96) 0.04 
Model 1: Unadjusted, stratified by center. Model 2: Adjusted for, sex, age, education (no high school/some high school/completed 
high school), smoking status (never, former, current), drinking status (never, former, current), and BMI. 
† Model 2 for kidney cancer was further adjusted for estimated glomerular filtration rate (<60, ≥60 ml/min/1.72m2) and 
hypertension status (yes/no) †† Model 2 for breast cancer was further adjusted for menopausal status and parity. 
 *Models comparing the 80th vs 20th percentiles of urine arsenic distributions and associated p-trend were obtained from Cox 
proportional hazards models with log-transformed arsenic as a continuous variable. 
**p trend calculated modeling log-arsenic as continuous
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Figure 4.1 Hazard ratios (95%CI) for cancer mortality by urine arsenic concentrations.  
 
          
 
Lines represent the hazard ratio (thick line) and 95% confidence intervals (thin line) for overall and specific 
cancer mortality based on restricted cubic splines for log-transformed sum of inorganic and methylated species 
with knots at the 10th (3.8 µg/g creatinine), 50th (9.7 µg/g) and 90th (24.0 µg/g) percentiles. The reference was 
set at the 10th percentile of arsenic distribution. Models were adjusted for age, sex, education (no high 
school/some high school/completed high school), smoking status (never, former, current), drinking status 
(never, former, current) and BMI (kg/m2). Vertical bars represent the histogram of arsenic distribution in the 
study population. 
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Figure 4.2 Hazard ratios (95%CI) for cancer mortality comparing the 80
th
 to the 20
th
 
percentiles of inorganic arsenic by participant characteristics at baseline. 
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4.1.3 Association between cadmium exposure and cancer mortality 
 After multivariate adjustment for age, sex, BMI, smoking status and pack-years 
(Table 4.4), the hazard ratios (95%CI) for overall and for smoking-related cancer mortality 
comparing the 80
th
 vs 20
th
 percentile of cadmium concentrations in urine were 1.30 (1.09-
1.55) and 1.56 (95%CI: 1.24-1.96), respectively. The corresponding hazard ratios (95%CI) 
for cancers of the lung and pancreas were 2.27 (1.58-3.27) and 2.40 (1.39-4.17), 
respectively. After removing current smokers, the hazard ratios (95%CI) for overall, 
smoking-related, pancreatic and lung cancer mortality were 1.17 (0.93-1.48), 1.37 (1.00-
1.87), 2.00 (0.99-2.08) and 2.06 (1.15-3.70). Cadmium was not associated with other 
cancers. When modeling the dose-response relationship using restricted cubic splines, we 
found increased risks with increasing urine cadmium concentrations for overall, smoking-
related, lung and pancreatic cancer mortality, with no statistically significant departures 
from linearity (Figure 4.3).  
In subgroup analyses, the fully-adjusted hazard ratio for all-cancer mortality and for 
smoking-related cancer mortality comparing the 80
th
 vs 20
th
 percentiles of cadmium was 
consistent for all participants’ subgroups including smoking status, although the association 
seemed stronger among current smokers (Figure 4.4).  
Analyses investigating cadmium as a possible mediator of the association between 
tobacco smoke and lung cancer mortality showed that the percentage of cancer deaths due to 
tobacco smoking that could be attributed to cadmium was 9.0% (95%CI: 2.8%-21.8%).  
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Table 4.4 Hazard ratios (95% CI) for cancer mortality by urine cadmium concentrations 
 Cadmium tertiles  80
th
 vs 20
th
  
 ≤0.70 0.71-1.22 ≥1.23 percentiles* p-trend** 
Overall cancer (ICD-9 140 to 208) 
Cases / Total 77/1269 142/1266 156/1257 375/3792  
Model 1 1 (Referent) 1.80 (1.36,2.38) 1.94 (1.47,2.57) 1.36 (1.16,1.59) <0.001 
Model 2 1 (Referent) 1.76 (1.32,2.35) 1.85 (1.36,2.51) 1.30 (1.09,1.55) <0.001 
Smoking related cancers*** (ICD-9 140-149, 150-151, 153-155, 157, 161, 162, 180, 188-189, 205) 
Cases / Total 34/1269 72/1266 104/1257 210/3792  
Model 1 1 (Referent) 2.04 (1.36,3.07) 2.81 (1.90,4.16) 1.56 (1.28,1.91) <0.001 
Model 2 1 (Referent) 2.04 (1.34,3.11) 2.80 (1.82,4.31) 1.56 (1.24,1.96) <0.001 
Esophagus and Stomach cancer (ICD-9 150-151) 
Cases / Total 11/1269 6/1266 7/1257 24/3792  
Model 1 1 (Referent) 0.55 (0.20,1.49) 0.68 (0.26,1.79) 0.63 (0.33,1.20) 0.16 
Model 2 1 (Referent) 0.60 (0.21,1.68) 0.76 (0.26,2.23) 0.68 (0.34,1.38) 0.29 
Colon and rectal cancer (ICD-9 153-154) 
Cases / Total 6/1269 14/1266 12/1257 32/3792  
Model 1 1 (Referent) 2.27 (0.87,5.93) 1.76 (0.65,4.75) 1.06 (0.60,1.86) 0.84 
Model 2 1 (Referent) 2.23 (0.82,6.02) 1.74 (0.60,5.11) 0.98 (0.51,1.88) 0.96 
Liver and intrahepatic bile ducts (ICD-9 155) 
Cases / Total 4/1269 7/1266 10/1257 21/3792  
Model 1 1 (Referent) 1.79 (0.52,6.14) 2.83 (0.87,9.14) 1.51 (0.81,2.81) 0.20 
Model 2 1 (Referent) 2.11 (0.59,7.55) 3.67 (1.01,13.32) 1.64 (0.81,3.13) 0.14 
Gallblader and extrahepatic bile ducts (ICD-9 156) 
Cases / Total 3/1269 5/1266 3/1257 11/3792  
Model 1 1 (Referent) 1.56 (0.37,6.57) 0.94 (0.19,4.77) 1.13 (0.44,2.86) 0.80 
Model 2 1 (Referent) 1.28 (0.29,5.67) 0.66 (0.11,3.90) 0.89 (0.31,2.54) 0.82 
Pancreas (ICD-9 157)† 
Cases / Total 12/1269 - 12/1257 24/3792  
Model 1 1 (Referent) - 2.00 (0.89,4.52) 2.00 (1.19,3.36) 0.009 
Model 2 1 (Referent) - 2.47 (1.01,6.03) 2.40 (1.39,4.17) 0.002 
Bronchus and lung (ICD-9 162) 
Cases / Total 4/1269 21/1266 52/1257 77/3792  
Model 1 1 (Referent) 4.85 (1.66,14.1) 10.2 (3.67,28.4) 2.33 (1.76,3.09) <0.001 
Model 2 1 (Referent) 3.39 (1.14,10.1) 6.65 (2.29,19.3) 2.27 (1.58,3.27) <0.001 
Breast (ICD-9 174) 
Cases / Total 6/504 12/786 7/964 25/1538  
Model 1 1 (Referent) 1.29 (0.48,3.47) 0.60 (0.20,1.83) 1.01 (0.51,1.98) 0.15 
Model 2 1 (Referent) 1.34 (1.14,10.1) 0.58 (0.18,1.83) 1.02 (0.50,2.07) 0.96 
 Prostate (ICD-9 185)  
Cases / Total 4/761 8/472 4/289 16/3792  
Model 1 1 (Referent) 1.80 (0.54,6.00) 0.85 (0.2,3.48) 0.70 (0.30,1.62) 0.41 
Model 2 1 (Referent) 1.37 (0.40,4.66) 0.48 (0.11,2.08) 0.42 (0.16,1.08) 0.07 
Kidney (ICD-9 189) 
Cases / Total 8/1269 11/1266 6/1257 26/3792  
Model 1 1 (Referent) 1.40 (0.56,3.50) 0.82 (0.28,2.42) 0.83 (0.44,1.56) 0.64 
Model 2 1 (Referent) 1.92 (0.73,5.01) 1.39 (0.43,4.58) 1.15 (0.58,2.31) 0.61 
Lymphohematopoietic tissue (ICD-9 200–208) 
Cases / Total 6/1269 17/1266 14/1257 37/3792  
Model 1 1 (Referent) 2.96 (1.16,7.52) 2.73 (1.04,7.20) 1.45 (0.87,2.40) 0.15 
Model 2 1 (Referent) 2.94 (1.12,7.70) 2.79 (0.99,7.90) 1.40 (0.80,2.43) 0.24 
Model 1: Unadjusted, stratified by center. Model 2: Adjusted for sex, age, smoking status (never, former, current),number of packs-per 
year and BMI (kg/m2). Model 2 for breast cancer was further adjusted for menopausal status, parity and hormonal replacement use. 
Model 2 for kidney cancer was further adjusted for estimated glomerular filtration rate (continuous) and hypertension status (yes,no). † 
Tertiles 1 and 2 are combined because there was only one case in the first tertile. *Models comparing the 80th vs 20th percentiles of urine 
cadmium and associated p-trend were obtained from Cox proportional hazards models with log-transformed cadmium as a continuous 
variable. **p-trend calculated modeling log-cadmium as continuous. *** Smoking related cancers: Lip, oral cavity and pharynx (140-
149), esophagus (150), stomach (151), colon and rectum (153-154), liver (155), pancreas (157), larynx (161), trachea, bronchus and lung 
(162), cervix (180), bladder (188), kidney (189), myeloid leukemia (205). 
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Figure 4.3 Hazard ratios (95%CI) for cancer mortality by urine cadmium concentrations 
 
 
 
 
 
Hazard ratios (95% confidence intervals) for overall, smoking-related, lung and pancreas cancer mortality based on 
restricted cubic splines for log-transformed urine cadmium concentrations with knots at the 10th, 50th and 90th percentile. 
The reference value is set at the 10th percentile of the cadmium distribution. Hazard ratios are adjusted for sex, age, 
smoking status, pack-years and BMI. 
Vertical bars represent the histogram of urine cadmium distribution 
 
 
 
 
 Figure 4.4 Hazard ratios (95%CI) for cancer mortality comparing the 80
th
 to the 20
th
 percentiles of cadmium by participant 
characteristics at baseline.
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4.2 Results for objective 2 
 
4.2.1 Characteristics of the sample  
 Table 4.5 shows the main socio-demographic characteristics and anthropometric 
measurements among breast cancer cases and controls by menopausal status, and among 
prostate cancer cases and controls. Both pre-and postmenopausal cases had lower 
education levels, while postmenopausal cases were slightly younger than their controls. 
Although the percentage of obese women in premenopausal cases was lower than in 
controls, postmenopausal cases were more likely to have higher self-reported values of 
weight at age 45 and BMI 1 year prior to the interview, as well as greater WC and WHR 
at the time of the interview. On average, prostate cancer cases reached their maximum 
weight one year later, weighted less at age 45, and were shorter than their controls. 
Additionally, prostate cancer cases presented a larger WHR at the time of the interview.  
 Cases were interviewed within 60 (BC) or 80 (PC) days from their diagnosis. 
Interviewers classified participant responses as follows: fair (6% for breast and 2% for 
prostate participants), good (46% for breast and 37% for prostate) or excellent (48% for 
breast and 59% for prostate). Results from the Pearson´s correlation test indicated a 
high intra-observer reproducibility of measurements (r=0.99 for all of them). 
 The correlation coefficients between the different anthropometric variables can 
be found in table 4.6. Variables highly correlated (r≥0.60) with the “BMI 1 year prior to 
interview” included: “weight gain since age 20”, “weight at age 45” and “waist 
circumference at the time of the interview”.   
 
 
Table 4.5: MCC-Spain: Socio-demographic characteristics and anthropometric measurements among breast cancer cases and 
controls by menopausal status, and among prostate cancer cases and controls.  
Variable Premenopausal women Postmenopausal somwn Men 
 Cases 
(N=623) 
Controls 
(N=537) 
p-val Cases 
(N=864) 
Controls 
(N=963) 
p- 
val 
Cases 
(N=1018) 
Controls 
(N=1327) 
p- 
val 
Socio-demographic factors          
Age (mean, SD) 45.1 (7.8) 45.5 (9.4) 0.36 63.3 (8.9) 64.5 (9.5) <0.01 66.0 (7.24) 66.6 (8.28) 0.05 
Study level, N (%)          
< Primary 17     (3)  22 ( 4)  194 (22)  194 (21)  235 (23) 257 (19)  
Primary 147 (24)  106 (20)  337 (29)  341 (35)  411 (41) 436 (33)  
High School 270 (43) 211 (39)  223 (26)  270 (28)  214 (21) 361 (27)  
>High School 189 (30) 198 (37) 0.04 110 (13)  158 (16) 0.05 158 (15) 273 (21) <0.01 
Reproductive factors          
Age of menarche (mean, SD) 12.7 (1.4) 12.7 (1.5) 0.32 12.9 (1.6)  12.9 (1.7) 0.95 - - - 
Age at first birth age (mean, SD)  27.8 (0.7) 27.7 (0.7)  26.2 (4.5)  26.5 (4.5) 0.24 - - - 
Anthropometric variables*          
Age reached maximum height (mean, SD) 15.9 (2.4) 16.1 (2.6) 0.18 15.8 (2.5)  16.3 (2.9) <0.01 19.5 (2.7) 19.4 (2.7) 0.92 
Age reached maximum weight (mean, SD) 39.7 (11.0) 39.0(0.49) 0.36 54.7 (0.5)  54.6 (14.9) 0.90 58.0 (13.6) 57.1 (14.2) 0.15 
Weight at age 20 (mean, SD) 54.7 (7.7) 55.3 (9.2) 0.22 54.0 (9.3)  53.8 (8.6) 0.77 65.4 (9.5) 65.9 (9.7) 0.35 
Weight at age 45 (mean, SD) 63.3 (11.8) 62.0(11.9) 0.17 63.2(12.5)  61.0 (11.3) <0.01 73.1 (11.5) 74.2 (11.2) 0.03 
Weight gain since age 20 (mean, SD) 8.7 (10.0) 8.4(10.3) 0.58 14.5(12.1)  12.5 (11.3)  13.7 (11.6) 13.9 (12.2) 0.82 
Height meters (1-yr before diagnosis) 1.62 (0.06) 1.62 (0.06) 0.21  1.58 (0.1) 1.59 (0.06) 0.33 1.69 (0.07) 1.70 (0.07) 0.01 
BMI (1-yr before interview), N (%)          
 20-24 402 (64) 345 (64)  297 (34)  426 (44)  254 (25) 328 (25)  
 25-29 167 (27) 125 (23)  346 (40) 341 (35)  529 (52) 691 (52)  
>29 54 (9) 67 (13) 0.07 221 (26) 196 (21) <0.01 235 (23) 308 (23) 0.99 
Waist Ø (tertiles), N (%)          
Women <82; Men <98 cm 268 (45) 272 (51)  140 (17) 215 (22)  300 (33) 424 (32)  
Women 82-93.5; Men 98-106 cm 193 (33) 156 (29)  269 (34) 340 (36)  316 (25) 442 (34)  
Women: ≥93.5; Men ≥106 cm  132 (22) 104 (20) 0.14 392 (49) 396 (42) <0.01 295 (32) 447 (34) 0.71 
Waist-to-hip ratio (tertiles), N (%)          
Women: <0.81; Men <0.94 cm 285 (48) 279 (53)  172 (22) 233 (25)  248 (28) 436 (33)  
 Women 0.81-0.88; Men 0.94-0.99 cm 184 (31) 155 (29)  256 (32) 336 (35)  302 (33) 435 (33)  
Women ≥0.88; Men ≥0.99 cm 124 (21) 98 (18) 0.32 371 (46) 382 (40) 0.03 356 (39) 441 (33) <0.05 
Family history of breast cancer          
None 507 (81) 488 (91)  730 (84) 855 (89)  847 (83) 1249 (94)  
1 first  degree 83 (13) 37 (7)  106 (2) 87 (9)  8 (1) 3 (0.2)  
>1 first degree 12 (2) 0 (0)  15 (12) 10 (1)  137 (13) 72 (5.6)  
≥1 second degree 21 (4) 12 (2) <0.01 13 (2) 11 (1) 0.06 26 (3) 3 (0.2) <0.05 
Previous biopsies          
No 571 (92) 521 (97)  768 (89) 949 (99)  - - - 
Yes 52 (8) 16 (3) <0.01 96 (11) 14 (1) <0.01 - - - 
Data in the table are percentages for categorical variables or means ± SD for continuous variables.  
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Table 4.6: MCC-Spain: Correlation coefficients between the studied anthropometric 
variables by sex  
         
 Age 
max 
height 
Age 
max 
weight 
Weight 
age 20 
Weight 
age 45 
Weight 
gain 
BMI Waist 
circumference 
Waist-
hip 
ratio 
Women         
Age max 
height 
1.00        
Age max 
weight 
0.06* 1.00       
Weight age 
20 
0.07* -0.17*       
Weight age 
45 
0.06* 0.00 0.54* 1.00     
Weight 
gain 
0.07* 0.44* -0.27* 0.35*     
BMI 0.07* 0.36* 0.32* 0.60* 0.74* 1.00   
Waist Ø 0.05* 0.39* 0.27* 0.51* 0.62* 0.76* 1.00  
Waist-hip 
ratio 
-0.01 0.27* 0.02 0.15* 0.29* 0.34* 0.63* 1.00 
Men         
Age max 
height 
1.00        
Age max 
weight 
0.04 1.00       
Weight age 
20 
-0.00 -0.23* 1.00      
Weight age 
45 
0.00 -0.18* 0.64* 1.00     
Weight 
gain 
0.01 0.36* -0.36* 0.14 1.00    
BMI -0.00 0.23* 0.21* 0.43* 0.71* 1.00   
Waist Ø 0.05* 0.26* 0.22* 0.39* 0.58* 0.73* 1.00  
Waist-hip 
ratio 
0.12* 0.16* -0.02 0.06* 0.25* 0.29* 0.49* 1.00 
*p <0.05 according to Spearman´s correlation test 
 
4.2.2 Association between obesity and other related anthropometric factors and 
breast cancer risk. 
 Table 4.7 presents the ORs (95%CI) for the associations between the studied 
anthropometric variables and breast cancer risk. The age at maximum height was 
inversely associated with breast cancer risk (OR per year=0.95: 95%CI=0.95-0.99). An 
overall increased risk of breast cancer was observed with increasing weight at age 45 
(OR5 kg=1.05: 95%CI 1.00-1.11), increasing BMI (OR2 units=1.05: 95%CI 1.01-1.09) or 
WHR (OR0.10 units=1.11: 95%CI 0.99-1.26). Although a positive link was also observed 
for weight gain since age 20, this association disappeared when final BMI was taken 
into account. The right columns of table 4.7 present the analysis in pre- and 
postmenopausal women, and figure 4.5 shows the dose-response shape of the 
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association between BMI and WHR in both groups of women. Stratified analyses by 
menopausal status revealed that the effect of BMI and the WHR was mainly restricted 
to postmenopausal women (see also figure 4.5). Interestingly, these analyses also 
indicate that the association of breast cancer with WC in premenopausal women was 
only present after accounting for BMI, while in postmenopausal women this observed 
risk was independent of BMI.  
 Table 4.8 summarizes the results for breast cancer models by tumor subtypes. 
Similar associations with BMI, WC, WHR, weight at age 45 and age at maximum 
height were found for HR+/HER2-. HER2+ and TN cancers, both in pre-and 
postmenopausal women. Those variables associated to obesity earlier in like (“weight at 
age 20” and “age at maximum weight) were associated with a decreased risk of more 
aggressive tumor subtypes (HER2+ and triple negative) in premenopausal but not 
postmenopausal women. In postmenopausal women, significant heterogeneity of the 
ORs across intrinsic subtypes could be observed for “age at maximum weight” and for 
“weight gain since age 20”. Interestingly, in models that did not account for BMI, a 
positive association was seen between “weight gain since age 20” and the risk of 
HR+/HER2- tumors in postmenopausal women (OR=1.10; 95%CI:1.04.1.16); data not 
shown in tables. 
 In sensitivity analyses, results were similar when excluding interviews classified 
as “fair” (data not shown), as well as when analyses were further adjusted for diabetes 
status or stratified by BMI. Consistent findings were also found after exclusion of 
women who had received hormonal replacement therapy, although the ORs for all these 
variables in postmenopausal women were slightly higher (see table 4.9). 
  
 
 
Table 4.7: MCC-Spain: Odds ratios (95%CI) for the association between anthropometrical variables and breast cancer risk, overall and by menopausal status 
Model 1: Adjusted for age, study level (<Primary, Primary, High school, >High school), age at first birth (25-29, <20, 20-24,>29, nulliparous), age at menarche (12-13, <12, >13), 
previous biopsies (yes/no), family history of breast cancer. Models for the overall population are further adjusted for menopausal status. 
Model 2: Further adjusted for BMI (1-yr before diagnosis).  
p-het: p for heterogeneity of effects by menopausal status as estimated in model 2.  
  
OVERALL 
 
PREMENOPAUSAL 
 
POSTMENOPAUSAL 
p- 
het 
 N Model 1 Model 2 N Model 1 Model 2 N Model 1 Model 2  
 
Co Ca 
OR 
(95%CI) 
p- 
trend 
OR 
(95%CI) 
p-
trend 
Co Ca 
OR 
(95%CI) 
p-
trend 
OR 
(95%CI) 
p-
trend 
Co Ca 
OR 
(95%CI) 
p-
trend 
OR 
(95%CI) 
p-
trend 
 
Age maximum 
height (per year) 
 
1055 
 
1089 
0.95 
(0.91- 0.99) 
 
0.02 
0.95 
(0.91-0.99) 
 
<0.01 
 
428 
 
479 
0.99 
(0.91-1.03) 
 
0.35 
0.97 
(0.91-1.04) 
 
0.41 
 
627 
 
610 
0.95 
(0.90-0.99) 
 
0.03 
0.93 
(0.89-0.98) 
 
0.01 
 
0.84 
Weight at age 20  
(per 5 kg) 
 
1382 
 
1343 
1.03 
(0.98-1.08) 
 
0.31 
1.00 
(0.95-1.06) 
 
0.87 
 
510 
 
583 
1.02 
(0.94-1.11) 
 
0.63 
1.03 
(0.96-1.15) 
 
0.27 
 
872 
 
760 
1.03 
(0.96-1.09) 
 
0.46 
0.98 
(0.92-1.05) 
 
0.60 
 
0.79 
Weight at age 45 
(per 5 kg) 
 
1163 
 
1124 
1.08 
(1.03-1.12) 
 
<0.01 
1.05 
(1.00-1.11) 
 
0.07 
 
285 
 
344 
1.05 
(0.97-1.14) 
 
0.24 
1.13 
(1.00-1.28) 
 
0.05 
 
878 
 
780 
1.09 
(1.03-1.14) 
 
<0.01 
1.04 
(0.98-1.10) 
 
0.22 
 
0.46 
Age maximum 
weight (5 years) 
 
1445 
 
1435 
1.02 
(0.99-1.06) 
 
0.22 
1.01 
(0.97-1.05) 
 
0.61 
 
528 
 
600 
1.04 
(0.96-1.13) 
 
0.30 
1.06 
(0.97-1.14) 
 
0.19 
 
917 
 
835 
1.02 
(0.97-1.06) 
 
0.47 
0.99 
(0.95-1.03) 
 
0.67 
 
0.11 
Weight gain since 
age 20 (per 5 kg) 
 
1339 
 
1312 
1.04 
(1.01-1.08) 
 
0.05 
1.00 
(0.95-1.07) 
 
0.90 
 
477 
 
555 
0.97 
(0.90-1.04) 
 
0.40 
1.00 
(0.90-1.12) 
 
1.00 
 
862 
 
757 
1.08 
(1.04-1.14) 
 
<0.01 
1.01 
(0.94-1.09) 
 
0.79 
 
0.45 
BMI                     
20-24 771 699 1.00  -  345 402 1.00  -  426 297 1.00  -   
 
25-29 
 
466 
 
513 
1.32 
(1.09-1.60) 
 -  
 
125 
 
167 
1.22 
(0.88-1.67) 
 -  
 
341 
 
346 
1.49 
(1.17-1.91) 
 -  
 
 
>29 
 
263 
 
275 
1.31 
(1.03-1.66) 
 
<0.01 
-  
 
67 
 
54 
0.66 
(0.41-1.06) 
 
0.45 
-  
 
196 
 
221 
1.71 
(1.28-2.28) 
 
<0.01 
-  
 
 
Per 2 units BMI 
 
1500 
 
1487 
1.05 
(1.01-1.09) 
 
<0.01 
- - 
 
537 
 
623 
0.97 
(0.90-1.03) 
 
0.28 
- - 
 
963 
 
864 
1.10 
(1.05-1.15) 
 
<0.01 
- - 
 
0.01 
Waist tertiles                    
<81.4 cm 487 408 1.00  1.00  272 268 1.00  1.00  215 140 1.00  1.00   
 
81.4-93.0 cm 
 
496 
 
462 
1.27 
(1.03-1.58) 
 
1.24 
(0.99-1.56) 
 
 
156 
 
193 
1.20 
(0.88-1.65) 
 
1.42 
(1.00-2.01) 
 
 
340 
 
269 
1.41 
(1.04-1.93) 
 
1.31 
(0.95-1.80) 
 
 
 
≥93.0 cm 
 
500 
 
524 
1.52 
(1.20-1.93) 
 
<0.01 
1.44 
(1.07-1.95) 
 
0.02 
 
104 
 
132 
1.19 
(0.81-1.75) 
 
0.27 
1.83 
(1.08-3.11) 
 
0.02 
 
396 
 
392 
1.90 
(1.04-1.93) 
 
<0.01 
1.54 
(1.04-2.28) 
 
0.03 
 
 
Per 10 cm waist 
 
1483 
 
1394 
1.12 
(1.04-1.20) 
 
<0.01 
1.06 
(0.95-1.18) 
 
0.33 
 
532 
 
593 
1.02 
(0.91-1.15) 
 
0.71 
1.18 
(0.98-1.42) 
 
0.08 
 
951 
 
801 
1.17 
(1.06-1.29) 
 
<0.01 
1.04 
(0.99-1.20) 
 
0.08 
 
0.56 
WHR tertiles                    
<0.81 537 465 1.00  1.00  279 285 1.00  1.00  233 172 1.00  1.00   
 
0.81-0.88 
 
532 
 
463 
1.22 
(0.99-1.51) 
 
1.18 
(0.95-1.47) 
 
 
155 
 
184 
1.30 
(0.94-1.79) 
 
1.39 
(1.00-1.93) 
 
 
336 
 
256 
1.20 
(0.89-1.61) 
 
1.13 
(0.83-1.52) 
 
 
 
≥0.88 
 
524 
 
537 
1.40 
(1.11-1.77) 
 
<0.01 
1.32 
(1.03-1.68) 
 
0.03 
 
98 
 
124 
1.22 
(0.83-1.80) 
 
0.20 
1.38 
(0.91-2.09) 
 
0.09 
 
382 
 
371 
1.57 
(1.15-2.13) 
 
<0.01 
1.39 
(1.01-1.91) 
 
0.04 
 
 
Per 0.1 units WHR 
 
1483 
 
1392 
1.15 
(1.02-1.30) 
 
<0.01 
1.11 
(0.99-1.26) 
 
0.08 
 
532 
 
593 
1.04 
(0.86-1.27) 
 
0.69 
1.10 
(0.89-1.36) 
 
0.39 
 
951 
 
799 
1.28 
(1.09-1.49) 
 
<0.01 
1.20 
(1.03-1.41) 
 
0.02 
 
0.14 
 
 
Table 4.8: MCC-Spain: Odds ratios (95%CI) for the association between the studied anthropometrical variables and breast cancer risk by menopausal 
status and histological subtype. 
 
 
PREMENOPAUSAL 
 
POSTMENOPAUSAL 
 CO HR+/HER2- HER2+ TN  CO HR+/HER2- HER2+ TN  
 N N 
OR 
(95%CI) 
p-
trend 
N 
OR 
(95%CI) 
p-
trend 
N 
OR 
(95%CI) 
p-trend 
p-
het* 
N N 
OR 
(95%CI) 
p-trend N 
OR 
(95%CI) 
p-trend N 
OR 
(95%CI) 
p-
trend 
p- 
het* 
Age maximum 
height 
(per year) 
 
 
428 
 
 
307 
 
0.98 
(0.91-1.05) 
 
 
0.62 
 
 
73 
0.97 
(0.86-1.09) 
 
 
0.56 
 
 
44 
0.99 
(0.86-1.13) 
 
 
0.87 
 
 
0.97 
 
 
627 
 
 
387 
 
0.95 
(0.90-1.01) 
 
 
0.08 
 
 
92 
 
0.89 
(0.80-0.98) 
 
 
0.02 
 
 
56 
 
0.93 
(0.83-1.05) 
 
 
0.27 
 
 
0.44 
Weight at age 
20 (per 5 kg) 
 
510 
 
355 
1.01 
(0.90-1.14) 
 
 
85 
0.82 
(0.71-0.95) 
0.03 
 
38 
0.88 
(0.72-1.08) 
 
 
0.85 
 
872 
 
483 
0.97 
(0.90-1.05) 
 
0.51 
 
107 
1.09 
(0.97-1.22) 
 
0.13 
 
75 
1.04 
(0.91-1.19) 
 
0.57 
 
0.12 
Weight at age 
45 (per 5 kg)* 
 
285 
 
244 
1.07 
(1.02-1.13) 
 
<0.01 
36 
1.04 
(0.95.1.13) 
0.43 25 
1.13 
(1.04-1.24) 
<0.01 
 
0.32 
 
878 
 
498 
1.03 
(0.96-1.10) 
 
0.40 
 
111 
1.00 
(0.90-1.12) 
 
0.99 
 
82 
1.10 
(0.99-1.23) 
 
0.08 
 
0.35 
Age maximum 
weight 
(per 5 years) 
 
 
528 
 
 
397 
 
1.04 
(0.95-1.12) 
 
 
0.45 
 
 
87 
 
1.13 
(0.96-1.33) 
 
 
0.19 
 
 
51 
 
1.24 
(0.98-1.56) 
 
 
0.07 
 
 
0.20 
 
 
917 
 
 
529 
 
1.00 
(0.96-1.05) 
 
 
0.88 
 
 
121 
 
1.05 
(0.96-1.15) 
 
 
0.29 
 
 
85 
 
0.89 
(0.83-0.97) 
 
 
<0.01 
 
 
<0.01 
Weight gain 
since age 20**  
(per 5 kg) 
 
477 
 
369 
1.05 
(0.94-1.17) 
 
0.37 
 
80 
1.08 
(0.92-1.30) 
 
0.39 
48 
1.18 
(0.92-1.51) 
0.20 
 
0.72 
 
862 
 
459 
1.03 
(0.95-1.12) 
 
0.47 
 
108 
0.89 
(0.79-1.01) 
 
0.07 
 
66 
0.94 
(0.82-1.08) 
 
0.41 
 
0.05 
BMI      -    -             
20-24 345 259 1.00  58 1.00  35 1.00   426 190 1.00  44 1.00  28 1.00   
25-29 
 
125 
 
121 
1.42 
(1.00-2.01) 
 
 
19 
1.00 
(0.55-1.81) 
 
 
13 
1.14 
(0.56-2.30) 
  
 
341 
 
219 
1.46 
(1.11-1.92) 
 
 
54 
1.73 
(1.10-2.72) 
 
 
30 
1.30 
(0.73-2.24) 
  
>29 
 
67 
 
33 
0.63 
(0.37-1.08) 
 
0.75 
 
14 
1.32 
(0.64-2.73) 
 
0.47 
 
4 
0.62 
(0.20-2.30) 
 
0.63 
 
 
196 
 
139 
1.64 
(1.19-2.26) 
 
<0.01 
 
27 
1.54 
(0.89-2.66) 
 
0.06 
 
30 
2.31 
(1.30-4.11) 
 
<0.01 
 
Per 2 units 
BMI 
 
537 
 
413 
0.97 
(0.91-1.05) 
 
0.48 
 
91 
1.05 
(0.94-1.17) 
 
0.41 
 
52 
0.93 
(0.80-1.09) 
 
0.38 
 
0.34 
 
963 
 
548 
1.10 
(1.05-1.16) 
 
<0.01 
 
125 
1.09 
(1.00-1.19) 
 
0.05 
 
88 
1.10 
(0.99-1.21) 
 
0.06 
 
0.97 
Waist tertiles                       
<81.4 cm 272 171 1.00  41 1.00  20 1.00   215 88 1.00  20 1.00  13 1.00   
81.4-93.0 cm 
 
156 
 
133 
1.55 
(1.06-2.26) 
 
 
27 
1.00 
(0.55-1.84) 
 
 
16 
1.93 
(0.88-4.24) 
  
 
340 
 
176 
1.29 
(0.90-1.86) 
 
 
32 
1.26 
(0.66-2.38) 
 
 
22 
1.06 
(0.50-2.27) 
  
≥93.0 cm 
 
104 
 
93 
2.19 
(1.22-3.90) 
 
<0.01 
 
19 
1.11 
(0.45-2.73) 
 
0.84 
 
9 
2.42 
(0.74-7.85) 
 
0.09 
 
 
396 
 
243 
1.39 
(0.90-2.15) 
 
0.17 
 
65 
2.45 
(1.22-4.93) 
 
<0.01 
 
44 
1.78 
(0.78-4.05) 
 
0.11 
 
Per 10 cm 
waist 
 
532 
 
397 
1.21 
(0.99-1.49) 
 
0.06 
 
87 
1.02 
(0.75-1.40) 
 
0.88 
 
45 
1.40 
(0.96-2.06) 
 
0.08 
 
0.40 
 
951 
 
507 
1.02 
(0.87-1.19) 
 
0.79 
 
117 
1.19 
(0.94-1.51) 
 
0.15 
 
79 
1.05 
(0.80-1.39) 
 
0.72 
 
0.42 
WHR tertiles                       
<0.81 279 156 1.00  37 1.00  15 1.00   233 106 1.00  21 1.00  19 1.00   
0.81-0.88 
 
155 
 
117 
1.1 
(0.82-1.57) 
 
 
25 
1.21 
(0.69-2.12) 
 
 
14 
0.69 
(0.39-1.26) 
  
 
336 
 
170 
1.15 
(0.82-1.62) 
 
 
37 
1.34 
(0.74-2.43) 
 
 
20 
0.68 
(0.34-1.34) 
  
≥0.88 
 
98 
 
81 
1.20 
(0.84-1.71) 
 
0.15 
 
17 
1.83 
(1.03-3.26) 
 
0.08 
 
6 
1.07 
(0.59-1.93) 
 
0.06 
 
 
382 
 
230 
1.30 
(0.91-1.86) 
 
0.15 
 
58 
1.94 
(1.07-3.51) 
 
0.02 
 
40 
1.14 
(0.60-2.17) 
 
0.46 
 
 
Per 0.1 units 
WHR 
 
532 
 
397 
1.08 
(0.85-1.36) 
 
0.52 
 
87 
1.12 
(0.77-1.62) 
 
0.58 
 
45 
1.33 
(0.84-2.13) 
 
0.23 
 
0.66 
 
951 
 
506 
1.17 
(0.99-1.39) 
 
0.09 
 
116 
1.35 
(1.02-1.80) 
 
0.04 
 
79 
1.12 
(0.81-1.56) 
 
0.51 
 
0.55 
Models are adjusted for age, study level (<Primary, Primary, High school, >High school), recruitment area, BMI 1-year before the interview (continuous) age at first birth (25-29, <20, 
20-24,>29, nulliparous), age at menarche (12-13, <12, >13), previous biopsies (yes/no), family history of breast cancer. Co:Control; p-het: p for heterogeneity among intrinsic subtypes.   
 
 
Table 4.9: MCC-Spain: Odds Ratios (95%CI) for the association between anthropometrical variables and breast cancer risk among non HRT users, 
overall and by menopausal status  
  
OVERALL 
 
PREMENOPAUSAL 
 
POSTMENOPAUSAL 
 N Model 1 Model 2 N Model 1 Model 2 N Model 1 Model 2 
 
Co Ca 
OR 
(95%CI) 
p-
trend 
OR 
(95%CI) 
p-
trend Co Ca 
OR 
(95%CI) 
p-
trend 
OR 
(95%CI) 
p-
trend Co Ca 
OR 
(95%CI) 
p-
trend 
OR 
(95%CI) 
p-
trend 
Age maximum 
height (per year) 
 
890 
 
965 
0.96 
(0.92-1.00) 
 
0.06 
0.96 
(0.91-0.99) 
 
0.04 
402 468 
0.96 
(0.90-1.03) 
 
0.26 
0.96 
(0.90-1.03) 
 
0.30 
488 497 
0.96 
(0.91-1.02) 
 
0.24 
0.95 
(0.89-1.00) 
 
0.10 
Weight at age 20  
(per 5 kg) 
 
1122 
 
1188 
1.04 
(0.99-1.10) 
 
0.14 
1.02 
(0.96-1.09) 
 
0.45 
 
473 
 
569 
1.01 
(0.93-1.11) 
 
0.74 
1.05 
(0.95-1.15) 
 
0.36 
 
649 
 
619 
1.06 
(0.99-1.14) 
 
0.11 
1.01 
(0.94-1.10) 
 
0.74 
Weight at age 45 
(per 5 kg) 
 
915 
 
965 
1.09 
(1.04-1.15) 
 
<0.01 
1.08 
(1.02-1.14) 
 
0.01 
 
259 
 
329 
1.07 
(0.98-1.16) 
 
0.15 
1.14 
(1.00-1.31) 
 
0.05 
 
656 
 
636 
1.11 
(1.05-1.18) 
 
<0.01 
1.07 
(1.00-1.15) 
 
0.04 
Age maximum 
weight  
(per 5 years) 
 
 
1172 
 
 
1262 
 
1.03 
(0.99-1.07) 
 
 
0.19 
 
1.02 
(0.97-1.06) 
 
 
0.46 
 
 
487 
 
 
584 
 
1.04 
(0.96-1.13) 
 
 
0.29 
 
1.06 
(0.97-1.15) 
 
 
0.19 
 
 
685 
 
 
678 
 
1.02 
(0.97-1.07) 
 
 
0.38 
 
0.99 
(0.95-1.05) 
 
 
0.83 
Weight gain since 
age 20 (per 5 kg) 
 
1088 
 
1159 
1.04 
(1.00-1.08) 
 
0.09 
0.99 
(0.93-1.06) 
 
0.87 
 
442 
 
541 
0.98 
(0.90-1.05) 
 
0.52 
1.01 
(0.90-1.13) 
 
0.97 
 
646 
 
618 
1.08 
(1.02-1.14) 
 
<0.01 
0.99 
(0.91-1.07) 
 
<0.01 
BMI  
  
    
  
   
 
 
  
    
20-24 637 637 1.00  -  320 392 1.00  -  317 245 1.00  -  
25-29  
363 
 
434 
1.28 
(1.04-1.58) 
 -   
116 
 
161 
1.19 
(0.85-1.67) 
 -   
247 
 
273 
1.50 
(1.12-1.99) 
 -  
>29  
209 
 
237 
1.29  
(1.00-1.68) 
 
0.03 
-   
59 
 
53 
0.68 
(0.41-1.13) 
 -   
150 
 
184 
1.77 
(1.27-2.45) 
 
<0.01 
-  
Per 2 units BMI  
1209 
 
1308 
1.05 
(1.00-1.09) 
 
0.03 
-   
495 
 
606 
0.97 
(0.90-1.04) 
 
0.36 
-   
714 
 
702 
1.10 
(1.05-1.17) 
 
<0.01 
-  
Waist tertiles                   
<81.4 cm 434 407 1.00  1.00  252 260 1.00  1.00  158 103 1.00  1.00  
81.4-93.0 cm  
398 
 
380 
1.25 
(1.00-1.58) 
 1.25 
(0.98-1.60) 
  
144 
 
189 
1.22 
(0.88-1.70) 
 1.39 
(0.97-2.00) 
  
259 
 
216 
1.44 
(1.00-2.06) 
 1.35 
(0.93-1.97) 
 
≥93.0 cm  
363 
 
439 
1.53 
(1.18-1.98) 
 
<0.01 
1.52 
(1.09-2.14) 
<0.01  
96 
 
128 
1.10 
(0.73-1.64) 
 
0.47 
1.54 
(0.88-2.71) 
 
0.08 
 
286 
 
332 
2.14 
(1.48-3.09) 
 
<0.01 
1.80 
(1.14-2.85) 
 
0.01 
Per 10 cm waist  
1195 
 
1226 
1.11 
(1.02-1.20) 
 
0.01 
1.10 
(0.97-1.24) 
 
0.13 
 
492 
 
577 
1.01 
(0.87-1.14) 
 
0.87 
1.13 
(0.93-1.38) 
 
0.21 
 
703 
 
649 
1.23 
(1.10-1.37) 
 
<0.01 
1.14 
(0.97-1.35) 
 
0.11 
WHR tertiles                   
<0.81 410 363 1.00  1.00  264 280 1.00  1.00  170 127 1.00  1.00  
0.81-0.88  
403 
 
405 
1.26 
(1.00-1.58) 
 1.23 
(0.97-1.55) 
  
142 
 
176 
1.26 
(0.90-1.76) 
 1.35 
(0.95-1.90) 
  
256 
 
204 
1.30 
(0.92-1.85) 
 1.22 
(0.86-1.74) 
 
≥0.88  
382 
 
460 
1.52 
(1.18-1.97) 
 
<0.01 
1.46 
(1.12-1.91) 
 
<0.01 
 
86 
 
121 
1.25 
(0.83-1.89) 
 
0.18 
1.41 
(0.90-2.19) 
 
0.08 
 
277 
 
318 
1.84 
(1.29-2.64) 
 
<0.01 
1.64 
(1.14-2.38) 
 
<0.01 
Per 0.1 units WHR  
1195 
 
1228 
1.24 
(1.08-1.41) 
 
<0.01 
1.21 
(1.05-1.39) 
 
<0.01 
 
492 
 
577 
1.08 
(0.88-1.33) 
 
0.45 
1.15 
(0.91-1.44) 
 
0.24 
 
703 
 
649 
1.42 
(1.18-1.71) 
 
<0.01 
1.34 
(1.12-1.62) 
 
<0.01 
Model 1: Adjusted for age, study level (<Primary, Primary, High school, >High school), age at first birth (25-29, <20, 20-24,>29, nulliparous), age at menarche (12-13, <12, >13), 
previous biopsies (yes/no), family history of breast cancer. Models for the overall population are further adjusted for menopausal status. 
Model 2: Further adjusted for BMI (1-yr before diagnosis). 
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Figure 4.5: Odds ratio (95%CI) for the association between body mass index (BMI), 
waist to hip ratio (WHR) and breast cancer incidence (overall and by menopausal 
status). 
 
 
 
Lines represent the ORs (thick lines) and 95% CIs (dotted lines) for breast cancer based on restricted 
cubic splines for log transformed BMI and WHR with knots at the 10
th
 50
th
 and 90
th
 percentiles of their 
respective distributions. The reference was set at the 10
th
 percentile of BMI and WHR distributions. 
Models account for age, study level, recruitment area, age of menarche, age at first birth, menopausal 
status, existence of previous biopsies and family history of breast cancer. Models for the WHR also 
account for BMI. 
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4.2.3 Association between obesity and other related anthropometric factors and 
prostate cancer risk. 
 Table 4.10 displays the ORs (95%CI) for the associations between the studied 
anthropometric variables and prostate cancer risk, overall and by Gleason score at 
diagnosis. The WHR was the only variable significantly associated with an overall 
increased risk of this tumor. When analyses were stratified by Gleason score, OR tended 
to be higher for cancers with Gleason scores >6 (OR0.1 units: 1.21; 95%CI: 1.03-1.43), 
but no statistically significant differences between low and high grade tumors were 
observed. However, age at maximum weight was associated with an increased risk of 
high-grade prostate cancers (OR5 years: 1.05; 95%CI: 1.00-1.10; p-heterogeneity=0.09). 
On the contrary, an almost significant inverse association of BMI with low-grade 
tumors was found (OR2 units: 0.94; 95%CI: 0.88-1.01), while the OR for high-grade 
tumors went on the opposite direction and was not statistically significant (OR2 units: 
1.00; 95%CI: 0.94-1.07). Similar to what is shown for breast cancer, figure 4.6 presents 
the dose-response association for BMI and the WHR, in this case overall and by 
Gleason score at diagnosis. Again results were very similar when excluding interviews 
classified as “fair”, when adjusting for self-reported diabetic status or when stratifying 
the analyses by BMI (data not shown). 
 
 
 
Table 4.10: MCC-Spain: Odds ratios (95%CI) for the association between the studied anthropometric variables and prostate cancer: 
overall and by Gleason Score at diagnosis 
 N Model 1 Model 2 Gleason ≤6  Gleason > 6   
 
Controls Cases 
OR 
(95%CI) 
p- 
trend 
OR 
(95%CI) 
p-
trend 
N 
OR 
(95%CI) 
p-trend N 
OR 
(95%CI) 
p-
trend 
p-het 
Age maximum 
height (per year) 
 
852 
 
770 
0.98  
(0.94-1.05) 
 
0.52 
0.98 
(0.94-1.02) 
 
0.52 
 
307 
0.97 
(0.93-1.05) 
 
0.62 
 
351 
0.99 
(0.94-1.05) 
 
0.75 
 
0.86 
Weight at age 20  
(per 5 kg) 
 
1158 
 
920 
1.01 
(0.94-1.06) 
 
0.72 
1.01 
(0.96-1.07) 
 
0.60 
 
355 
1.02 
(0.95-1.09) 
 
0.65 
 
387 
1.00 
(0.93-1.07) 
 
0.95 
 
0.64 
Weight at age 45* 
(per 5 kg) 
 
1129 
 
955 
0.97 
(0.95-1.01) 
 
0.16 
0.97 
(0.93-1.02) 
 
0.26 
 
368 
0.96 
(0.90-1.02) 
 
0.17 
405 0.98 
(0.92-1.04) 
 
0.53 
 
0.47 
Age maximum 
weight  
(per 5 years) 
 
 
1178 
 
 
977 
 
1.02 
(0.98-1.05) 
 
 
0.40 
 
1.03 
(0.99-1.07) 
 
 
0.20 
 
 
387 
 
1.00 
(0.95-1.05) 
 
 
0.97 
 
 
411 
 
1.05 
(1.00-1.10) 
 
 
0.05 
 
 
0.09 
Weight gain since 
age 20 (per 5 kg) 
 
1055 
 
920 
0.97 
(0.93-1.01) 
 
0.19 
0.98 
(0.92-1.04) 
 
0.49 
 
355 
0.97 
(0.89-1.05) 
 
0.42 
 
387 
1.00 
(0.92-1.07) 
 
0.87 
 
0.56 
BMI               
20-24 328 254 1.00  -  103 1.00  102 1.00   
 
25-29 
 
691 
 
529 
0.93 
(0.74-1.17) 
 -   
214 
0.93 
(0.70-1.25) 
  
230 
1.02 
(0.78-1.37) 
  
 
>29 
 
308 
 
235 
0.88 
(0.67-1.15) 
 
0.34 
-   
84 
0.77 
(0.54-1.09) 
 
0.15 
 
98 
0.92 
(0.65-1.30) 
 
0.65 
 
 
Per 2 units BMI 
 
1327 
 
1018 
0.98 
(0.93-1.02) 
 
0.40 
-   
401 
0.94 
(0.88-1.01) 
 
0.08 
 
430 
1.00 
(0.94-1.07) 
 
0.92 
 
0.10 
Waist tertiles              
<81.4 cm 424 300 1.00  1.00  127 1.00  114 1.00   
 
81.4-93.0 cm 
 
442 
 
316 
1.01 
(0.80-1.28) 
 1.03 
(0.80-1.32) 
  
136 
1.13 
(0.82-1.57) 
  
133 
1.16 
(0.84-1.61) 
  
 
≥93.0  cm 
 
447 
 
295 
0.96 
(0.75-1.22) 
 
0.74 
1.00 
(0.73-1.39) 
 
0.97 
 
88 
0.78 
(0.50-1.21) 
 
0.34 
 
144 
1.31 
(0.87-1.97) 
 
0.18 
 
 
Per  10 cm  waist 
 
1313 
 
911 
0.98 
(0.90-1.07) 
 
0.67 
1.00 
(0.87-1.14) 
 
0.97 
 
351 
0.96 
(0.80-1.15) 
 
0.68 
 
391 
1.12 
(0.94-1.33) 
 
0.21 
 
0.15 
WHR tertiles              
<0.81 436 248 1.00  1.00  108 1.00  89 1.00   
 
0.81-0.88 
 
435 
 
302 
1.14 
(0.90-1.46) 
 1.18 
(0.92-1.51) 
  
130 
1.32 
(0.96-1.83) 
  
131 
1.47 
(1.05-2.04) 
  
 
≥0.88 
 
441 
 
356 
1.25 
(0.98-1.60) 
 
0.07 
1.32 
(1.02-1.72) 
 
0.04 
 
111 
1.15 
(0.81-1.63) 
 
0.46 
 
168 
1.83 
(1.30-2.58) 
 
<0.01 
 
 
 
Per 10 units WHR 
 
1312 
 
906 
1.11 
(0.98-1.25) 
 
0.11 
1.13 
(0.99-1.30) 
 
0.08 
 
349 
1.18 
(0.99-1.40) 
 
0.06 
 
388 
1.21 
(1.03-1.43) 
 
0.02 
 
0.69 
Model 1: Adjusted for age, study level (<Primary, Primary, High school, >High school), recruitment area, family history of prostate cancer.   
Model 2: Further adjusted for BMI (1-yr before interview)  
p-het: p for heterogeneity of effects as estimated in model 2 
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Figure 4.6: Odds ratios (95%CI) for the association between body mass index (BMI), 
waist to hip ratio (WHR) and prostate cancer incidence, overall and by Gleason score.  
 
 
Lines represent the ORs (thick lines) and 95% CIs (dotted lines) for prostate cancer based on restricted 
cubic splines for log transformed BMI and WHR with knots at the 10
th
 50
th
 and 90
th
 percentiles of their 
respective distributions. The reference was set at the 10
th
 percentile of BMI and WHR distributions. 
Models account for age, study level, recruitment area, and family history of prostate cancer. Models for 
the WHR also account for BMI. 
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4.3 Results for objective 3 
4.3.1 Characteristics of the sample  
 Table 4.11 shows the main characteristics of the studied participants. Compared 
to their controls, breast cancer cases were slightly younger and had greater BMI values, 
while prostate cancer cases presented lower education levels. Among controls, PSA 
testing was more frequent in diabetic men. Diabetic women were older, had lower 
education levels and higher prevalence of obesity than their counterparts, while diabetic 
men presented lower education levels than non-diabetics. Interestingly, diabetic women 
were more likely to be diagnosed with triple negative tumors than those without 
diabetes. 
4.3.2 Association between diabetes, diabetes duration, diabetes treatment and 
breast cancer risk 
 Table 4.12 presents the results for the associations between diabetes status, 
diabetes management, duration of diabetes and breast cancer risk, overall and by 
intrinsic subtypes. After multivariate adjustment for age, study level, BMI, age at 
menarche, age at first birth, existence of previous biopsies and family history of breast 
cancer, diabetic women showed no overall increased risk of breast cancer (OR: 1.09; 
95%CI: 0.82-1.45). However, significant heterogeneity of the effect was observed by 
intrinsic subtypes (pheterogeneity=0.04), with a positive association being encountered for 
triple negative tumors (OR: 2.13; 95%CI: 1.25-3.63). Diabetic women under 
conservative management, as well as those under treatment with oral hypoglycemic 
agents, showed no overall increased risk of cancer, although again the results suggested 
a heterogeneous effect by tumor subtype. Conservative management was associated 
with a non-significant risk of developing HER2 tumors, while treatment with oral 
hypoglycemic agents alone showed a positive link with TN breast cancer. Diabetes 
treatment with insulin (with or without an oral hypoglycemic agent) was associated with 
an overall increased risk of breast cancer (OR: 2.14; 95%CI: 1.12-4.09), and this effect 
was similar across tumor subtypes. Moreover, when analyses were restricted to women 
under insulin treatment, a non-significant positive dose response association was 
observed between years of insulin use and breast cancer risk (OR: 1.10; 95%CI: 0.98-
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1.23). Interaction analyses revealed no effect modification of BMI on the association 
between diabetes or diabetes management and breast cancer risk (data not shown). 
 Analyses based on metformin use alone showed a heterogeneous effect of this 
drug over different tumor subtypes: while no effect was observed for HER2 or TN 
tumors, a reduced risk for HR+/HER2- breast cancer was seen with increasing years 
under metformin use (ORper year: 0.89; 95%CI: 0.80-0.99). Duration of treatment with 
sulfonylurea was associated with a non-significant increased risk of breast cancer (ORper 
year: 1.05; 95%CI: 0.98-1.13), after adjustment for insulin and metformin use. Although 
we could not evaluate the dose-response association between years of insulin glargine 
use and cancer risk due to a lack of power (N=11 women received this type of insulin), 
we found that women who had ever received insulin glargine (yes/no) had an increased 
risk of breast cancer when compared to women who had never received this drug before 
(OR: 4.97; 95%CI: 1.09-22.7).  
 To conclude with the results based on breast cancer, we evaluated the 
association between diabetes duration and breast cancer risk. No linear relationship was 
seen, although results suggested a potential u-shaped dose-response (see figure 4.7).  
  
 
 
 
Table 4.11: MCC-Spain: Main characteristics of the studied MCC-Spain population by diabetic and cancer status 
Data in the table are percentages for categorical variables or means ± SD for continuous variables.  
p-val1: p-value from chi-square or anova test for differences in the distribution of the studied variables by diabetic status. 
p-val2: p-value from chi-square or anova test for differences in the distribution of the studied variables by case/control status. 
Numbers in tables may differ because not all tumors could be classified according to intrinsic subtype (breast) or Gleason score (prostate). 
  
  Breast cancer  Prostate cancer  
  CASES CONTROLS  CASES CONTROLS  
  No DM 
(N=835) 
DM 
(N=81) 
p-val1 No DM 
(N=995) 
DM 
(N=99) 
p-val1 p-val2 No DM 
(N=916) 
DM 
(N=138) 
p-val1  No DM 
(N=1109) 
DM 
(N=232) 
p-
val1 
p-
val2 
Age  62.0 (8.7) 68.9 (8.0) <0.01 64.1 (9.14) 71.7 (8.4) <0.01 <0.01 65.8 (7.3) 67.2 (7.1) 0.05 66.0 (8.5) 69.3 (7.0) <0.01 0.06 
Study level No studies 168 (20.1) 33 (40.7)  192 (19.3) 41 (41.4)   198 (81.2) 46 (18.9)  204 (18.4) 55 (23.7)   
 <HS 319 (38.2) 27 (33.3)  357 (35.9) 32 (32.3)   355 (87.2) 52 (12.8)  366 (33.0) 74 (31.9)   
 HS 235 (28.1) 15 (18.6)  283 (28.4) 16 (16.2)   209 (88.9) 26 (11.1)  313 (28.2) 57 (24.6)   
 >HS 113 (13.5) 6 (7.4) <0.01 163 (16.4) 10 (10.1) <0.01 0.32 154 (91.7) 14 (8.3) <0.01 226 (20.4) 46 (19.8) 0.28 <0.01 
BMI <25 316 (37.8) 14 (17.3)  462 (46.4) 19 (19.2)   242 (26.4) 19 (13.8)  291 (26.2) 41 (17.7)   
 25-30 338 (40.5) 29 (35.8)  339 (34.1) 38 (38.4)   487 (53.2) 67 (48.5)  581 (52.4) 117 (50.4)   
 >30 181 (21.7) 38 (46.9) <0.01 194 (19.5) 42 (42.4) <0.01 <0.01 187 (30.4) 52 (37.7) <0.01 237 (21.4) 74 (31.9) <0.01 0.10 
Age menarche <12 171 (20.5) 13 (16.1)  213 (21.4) 23 (23.2)   - -  - -   
 12-13 378 (45.2) 39 (48.1)  445 (44.7) 33 (33.4)   - -  - -   
 >13 286 (34.3) 29 (35.8) 0.69 337 (33.9) 43 (43.4) 0.09 0.17 - -  - -   
Age first birth  27.0 (26.3) 27.0 (4.8) 0.21 26.0 (26.4) 27 (26.4) 0.97 0.75 - -  - -   
Family history studied  No 721 (86.4) 72 (88.9)  905 (91.0) 83 (83.8)   749 (81.8) 128 (92.8)  1043 (94.0) 217 (93.5)   
cancer Yes 114 (13.7) 9 (11.1) 0.52 90 (9.1) 16 (16.2) 0.02 <0.01 167 (18.2) 10 (7.3) <0.01 66 (6.0) 15 (6.5) 0.77 <0.01 
Previous biopsies No 742 (88.9) 76 (93.8)  979 (98.4) 98 (99.0)   - -  - -   
 Yes 93 (11.1) 5 (6.2) 0.17 16 (1.6) 1 (1.0) 0.65 <0.01 - -  - -   
Screening behaviours 
last 5 years 
               
PSA testing/  No    91 (8.8) 17(15.9)      302 (29.8) 43 (21.1)   
Mamogram Yes    949 (91.3) 90 (84.1) 0.02 <0.01    711 (70.2) 161 (78.9) 0.02 <0.01 
DM characteristics                
Duration of disease (yrs)  - 8.73 (7.9)  - 8.6 (7.1)  0.95  7.5 (8.6)   8.0 (10.0)  <0.01 
Treatment Conservative  - 14 (17.3)  - 21 (21.2)    12 (0.7)   30 (12.9)   
 Drugs - 67 (82.7)  - 78 (78.8)  0.51  126 (91.3)   202 (87.1)  0.21 
Tumor characteristics                
Bilateral No 798 (97.6) 79 (97.5)  - -   - -  - -   
 Yes 20 (2.4) 2 (2.5) 0.99 - -   - -  - -   
Histologic subtype Ductal 608 (85.0) 64 (87.7)  - -   - -  - -   
 Lobular 53 (7.4) 4 (5.5)  - -   - -  - -   
 Other 54 (7.6) 5 (6.9) 0.80 - -   - -  - -   
Intrinsic subtypes RH+, HER2- 529 (73.1) 51 (66.2)  - -   - -  - -   
 HER2+ 121 (16.7) 9 (11.7)  - -   - -  - -   
 Triple - 74 (10.2) 17 (22.1) 0.01 - -   - -  - -   
Gleason <6        368 (49.1) 43 (36.8)      
 ≥6        381 (50.9) 74 (63.2) 0.41     
 
 
 
Table 4. 12: MCC-Spain: Odds ratios (95CI%) for the association between diabetes, diabetes management and breast cancer, overall and by 
tumor subtype.  
 Overall HR+/HER2- HER2+ TN  
 Cases
N 
Control 
N 
OR (95CI) Cases 
N 
OR (95CI) Cases 
N 
OR (95CI) Cases 
N 
OR (95CI) p-het 
 
OVERALL POPULATION 
 
          
Diabetes            
Non-diabetic  835 995 1.00 529 1.00 121 1.00 74 1.00  
Diabetic 81 99 1.09 
(0.82-1.45) 
51 1.10 
(0.81-1.48) 
9 0.91  
(0.51-1.60) 
17 2.13  
(1.25-3.63) 
 
0.04 
Diabetes management           
Non-diabetic 835 995 1.00 529 1.00 121 1.00 74 1.00  
Diabetic, conservative management 14 21 1.10 
(0.62-1.95) 
6 0.89 
(0.35-2.02) 
5 2.00 
(0.90-4.45) 
1 *  
<0.01 
Diabetic, treatment with oral hypoglycemic agents 47 70 0.89 
(0.63-1.28) 
32 0.94  
(0.65-1.35) 
2 * 11 2.08  
(1.13-3.84) 
 
<0.01 
Diabetic, treatment with insulin (+/- oral hypoglycemic agents) 20 8 2.14  
(1.12-4.09) 
13 2.44  
(1.12-5.29) 
2 * 5 4.81  
(1.31-17.63) 
 
0.37 
 
DIABETIC POPULATION 
 
          
Metformin use (years)** 35 43 0.94 
(0.86-1.03) 
24 0.89 
(0.80-0.99) 
3 1.11 
(0.95-1.29) 
8 1.02 
(0.92-1.13) 
 
0.01 
Sulfonylurea use (years)** 18 24 1.05 
(0.98-1.13) 
13 1.03 
(0.93-1.13) 
1 * 4 1.10 
(1.00-1.20) 
 
0.40 
Insulin use (years)** 20 6 1.10 
(0.98-1.23) 
13 1.11 
(0.93-1.33) 
2 * 5 1.07 
(0.83-1.38) 
 
0.91 
Time since diagnosis of diabetes (years) 81 99 1.02 
(0.97-1.07) 
51 1.01 
(0.95-1.06) 
9 1.05 
(0.94-1.17) 
17 1.03 
(0.96-1.10) 
 
0.67 
Numbers in tables may differ due to lack of information on tumor receptors in some participants. 
*Values are not presented due to the small number of cases in these subgroups.**Based on participants who reported duration of treatment 
Models for diabetes and diabetes management are adjusted for age, study level (no studies/<high school/high school/>high school), BMI (continuous), age at menarche, age at first birth, 
existence of previous biopsies and family history of the studied cancer (none/ one first-degree/ more than one first-degree/second-degree).  
Models for metformin and sulfonylureafurther adjusted for insulin treatment (yes/no) and for treatment with other hypoglycemic agent (yes/no), models for insulin are adjusted for treatment with 
metformn (yes/no) or sulfonylurea (yes/no) while models for time since diagnosis of diabetes further adjusted for diabetes treatment regimen (conservative/oral hypoglycemic agents/insulin or 
both).  
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4.3.3 Association between diabetes, diabetes duration, diabetes treatment and 
prostate cancer risk. 
 Results for prostate cancer are presented in table 4.13. After multivariate 
adjustment for age, study level, BMI and family history of prostate cancer, an overall 
decreased risk of this tumor was observed (OR: 0.74; 95%CI: 0.58-0.94). By Gleason 
score, the association was mainly confined to low-grade tumors (OR: 0.70; 95%CI: 
0.46-0.90. pheterogeneity=0.06). Moreover, when effect modification by BMI was explored, 
only normoweight (OR: 0.64; 95%CI: 0.48-0.87), and not overweight/obese diabetic 
participants (OR: 0.98; 95%CI: 0.64-1.48) showed this protective effect for low-grade 
prostate tumors (p for interaction=0.02; data not shown in tables). 
 Overall, diabetic men under conservative management, as well as those treated 
with hypoglycemic agents alone, showed a decreased risk of prostate cancer, while this 
protective effect in those under insulin treatment was only observed against less 
aggressive tumors (OR: 0.48; 95% CI: 0.25-0.93). Analyses stratified by BMI revealed 
that the protective effect of hypoglycemic agents use was only observed among diabetic 
men who were normoweight [ORnormoweight (95%CI): 0.66 (0.46-0.93); ORoverweight or obese 
(95%CI): 1.01 (0.63-1.61); p interaction=0.04]. Results based on the diabetic population 
only, found no association between years of metformin (OR: 0.97; 95% CI: 0.92-1.02) 
sulfonylurea (OR: 0.96; 95%CI: 0.93-1.05) or insulin use (1.01; 95%CI: 0.97-1.09) and 
the risk of prostate cancer. Similarly, no association was observed with insulin glargine 
treatment (yes/no; N=8 men had ever received this insulin) (OR: 1.64; 95%CI: 0.54-
5.00). 
 Regarding diabetes duration, an almost significant inverse association was 
observed for prostate cancer (OR: 0.98; 95% CI: 0.94-1.00), and when modeling the 
dose-response relationship using restricted cubic splines no significant departures from 
linearity were observed (figure 4.7). The results of sensitivity analyses were similar to 
those from the main analyses, and we observed no effect modification by “screening 
habits” (data not shown in tables). 
 
 
 
Table 4.13: MCC-Spain: Odds ratios (95%CI) for the association between diabetes, diabetes management and prostate cancer in 
MCC-Spain, overall and by Gleason score.  
 
 Overall Gleason ≤6 Gleason >6  
 Cases 
N 
Controls 
N 
OR (95CI) Cases 
N 
OR (95CI) Cases 
N 
OR (95CI) p-
het 
 
OVERALL POPULATION 
 
        
Diabetes          
Non-diabetic  916 1109 1.00 368 1.00 381 1.00  
  Diabetic 138 232 0.74 
 (0.58-0.94) 
43 0.70 
(0.46-0.90) 
74 0.92 
(0.73-1.14) 
 
0.06 
Diabetes management         
Non-diabetic 916 1109 1.00 368 1.00 381 1.00  
Diabetic, conservative management 12 30 0.47 
(0.23-0.95) 
2 * 10 0.94 
(0.43-2.05) 
* 
 
Diabetic, treatment with oral hypoglycemic agents 97 160 0.76 
(0.58-1.00) 
35 0.77 
(0.54-1.11) 
48 0.87 
(0.66-1.15) 
 
0.51 
Diabetic, treatment with insulin (+/- oral hypoglycemic agents) 29 42 0.84 
(0.51-1.38) 
6 0.48 
(0.25-0.93) 
16 1.05 
(0.66-1.66) 
 
0.08 
 
DIABETIC POPULATION 
 
        
Duration of metformin use** 79 118 0.97 
(0.92-1.02) 
26 1.00 
(0.92-1.09) 
38 0.96 
(0.87-1.05) 
 
0.38 
Sulfonylurea use (years)** 35 58 0.96 
(0.93-1.05) 
10 0.92 
(0.83-1.04) 
16 0.99 
(0.88-1.06) 
 
0.44 
Insulin use (years)** 24 37 1.01 
(0.97-1.09) 
5 1.00 
(0.91-1.13) 
13 1.01 
(0.95-1.08) 
 
0.99 
Time since diagnosis of diabetes 138 232 0.98 
(0.94-1.00) 
43 0.94 
(0.87-1.00) 
74 0.97 
(0.92-1.01) 
 
0.38 
Numbers may differ due to lack of information on Gleason scores in some participants  
*Values are not presented due to the small number of cases in this group. **Based on participants who reported duration of treatment 
Models for diabetes and diabetes management are adjusted for age, study level (no studies/<high school/high school/>high school), BMI (continuous) and family history of 
prostate cancer (none/ one first-degree/ more than one first-degree/second-degree).  
Models for metformin and sulfonylureafurther adjusted for insulin treatment (yes/no) and for treatment with other hypoglycemic agent (yes/no), while models for time since 
diagnosis of diabetes further adjusted for diabetes treatment regimen (conservative/oral hypoglycemic agents/insulin or both).  
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Figure 4.7: Odds ratios (95%CI) for the association between diabetes duration and risk 
of breast and prostate cancers 
          
Odds ratios for “time since diabetes diagnosis” and cancer risk. Lines represent the odds 
ratios and 95% confidence intervals for breast and prostate cancer based on restricted 
cubic splines for log-transformed “time since diabetes diagnosis” with knots at the 10th (2 
years), 50th (7 years) and 90th (12 years) percentiles. The reference is set at the 10th 
percentile of the distribution. Models are adjusted for age, study level (no studies/<high 
school/high school/>high school), BMI (continuous), diabetes treatment (conservative; 
oral hypoglycemic drugs; insulin +/- oral hypoglycemic drugs) and family history of the 
studied cancer (none/ one first-degree/ more than one first-degree/second-degree). 
Models for breast cancer further adjust for age at menarche, age at first birth and 
existence of previous biopsies. 
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5 DISCUSSION 
88 
 
  
89 
 
5.1 Discussion related to objective one 
5.1.1 Arsenic and cancer mortality 
 
 In the Strong Heart Study, a US-based prospective cohort study, low to moderate 
inorganic arsenic exposure, as measured in urine, was associated with increased 
mortality from lung, prostate and pancreatic cancers over almost 20 years of follow-up. 
The associations persisted after adjustment for sociodemographic and behavioral cancer 
risk factors. Unexpectedly, arsenic exposure was associated with decreased mortality 
from lymphatic and hematopoietic cancers. Arsenic was not associated with kidney 
cancer, and for liver cancer the increased risk was small and statistically non-significant. 
Both tumors have been associated with high arsenic exposure in other populations 
(145;146). Overall, increasing urinary arsenic concentrations showed a positive but non-
significant association with total cancer mortality. Our results extend the associations of 
arsenic with lung and prostate cancer, observed previously only at high levels of 
exposure (145;147-149). In addition, we found supportive evidence for pancreatic 
cancer, a cancer with limited epidemiological evidence available.  
 
 Several studies have evaluated the association between lung cancer and high 
levels of arsenic exposure. In 10,591 participants from Southwestern Taiwan (148), the 
hazard ratios for lung cancer incidence were 1.09, 2.28, 3.03 and 3.29 for arsenic 
concentrations in drinking water of 10 to 99, 100 to 299, 30 to 699, and 700 µg/L or 
more, respectively, compared to less than 10 µg/L. In a case-control study from 
Antofagasia (Chile), the odds ratio for lung cancer comparing the highest (200-400 
µg/L) to the lowest (<10 µg/L ) categories of arsenic in drinking water was 8.9 (95%CI: 
4.0-196) (150). Lung cancer mortality was also increased among young adults in 
northern Chile who were exposed to high doses of arsenic in utero (151). 
 
 Regarding prostate cancer, ecologic evidence from Southwestern Taiwan, where 
the population was exposed to high levels of arsenic in drinking water from artesian 
wells, showed increased prostate cancer mortality compared with the overall Taiwanese 
population (38). Based on the Taiwanese evidence, the IARC concluded there was 
evidence for a dose-response relationship (37). In a population from Utah exposed to 
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moderate arsenic concentrations in drinking water, the SMR for prostate cancer 
compared to the overall US population was 1.48 (95%CI: 1.07-1.91) (152). 
 
 Epidemiological evidence for an association between arsenic and pancreas 
cancer is scarce. Japanese individuals exposed during infancy to high arsenic levels 
through contaminated milk showed an SMR for pancreatic cancer of 1.79 (95%CI: 
1.23-2.61) compared with unexposed (145). In a case-control study from Spain (153), at 
low-moderate arsenic in drinking water, the odds ratios for exocrine pancreatic cancer 
comparing the highest (≥0.11 µg/g) to lowest (≤0.05 µg/g) toenail arsenic quartiles was 
2.02 (1.08-3.78). 
 
 Few studies have evaluated the association between arsenic and overall cancer 
mortality. In a prospective cohort including 115,903 participants in Bangladesh, the 
hazard ratios (95%CI) for cancer mortality were 1.10 (0.77-1.59), 1.44 (1.06-1.95), 1.75 
(1.28-2.40) and 1.56 (1.06-2.30) comparing arsenic concentrations in drinking water of 
10 to 49, 50 to 149, 150 to 299, and 300 or more to less than 10 µg/L, respectively 
(154). 
 
 In occupational settings (155;156), and in infants exposed through milk powder 
(145), arsenic exposure has been associated with increased blood cancer mortality. 
Arsenic trioxide is used in the treatment of some leukemias such as promyelocytic 
leukemia (157), and is under investigation for multiple myeloma (158). Arsenic trioxide 
pharmacotherapy has been related to cytotoxicity and apoptosis in cancer cells (159). As 
we could not specifically evaluate the association between arsenic and specific 
lymphatic or hematopoietic cancers due to the small number of cases, this finding 
requires replication in other populations and needs to be interpreted with caution. 
 
 Evidence at low-moderate levels remains limited for most cancer. Bladder 
cancer has been the most frequently studied cancer at these levels of exposure, with 
inconsistent findings (44;152;160). For lung cancer, a case-control study conducted in 
New Hampshire and Vermont counties found an odds ratio for small-cell and 
squamous-cell carcinoma of 2.75 (95% CI 1.39-5.91) comparing toenail arsenic 
concentrations ≥0.114 vs. <0.05 µg/g. In our study, histological information was not 
available, and we cannot evaluate if the association found with lung cancer mortality 
was also related to those cancer types. Finally, at very low levels of exposure, a Danish 
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cohort of 57,053 participants found no association between arsenic in drinking water 
(mean 1.2 μg/L, range 0.05 to 25.3 μg/L) and lung, liver, bladder, kidney or prostate 
cancer incidences over 10 year of follow-up (44). Our study, conducted in a population 
exposed to low-moderate arsenic levels, extends previous evidence for mortality 
associated with several cancer types, but included too few cases to evaluate some cancer 
of interest, including bladder an skin cancers. 
 Recently, the National Research Council convened a committee to evaluate the 
health effects of arsenic risk because of controversy regarding the current US EPA 
arsenic standard in drinking water. This maximum contaminant levels of 10 μg/L was 
established on the basis of lung and bladder cancer risk in highly exposed populations 
from southwestern Taiwan, and the risk of arsenic exposure at lower doses was derived 
using linear low-dose extrapolation. Our findings offer useful information for risk 
assessment, as provide direct evidence at low-moderate levels and support a linear dose-
response relationship for lung, prostate and pancreatic cancers with no evidence of a 
threshold. 
5.1.2 Cadmium and cancer mortality 
 
 Low to moderate cadmium exposure, as measured in urine, was associated with 
increased mortality from overall, smoking-related, lung and pancreas cancer over almost 
20 years of follow-up. Our findings are consistent with previous cohort studies showing 
increased incidence and mortality for overall (72;161), lung (161-163), and pancreas 
cancers (78;79) in individuals with increased cadmium exposure. Contrary to other 
studies, however, we found no association with prostate (164-166), breast (74) or 
kidney cancer (77), although we had limited power to identify associations due to the 
small number of events. 
 Smoking, a cause of several cancers including lung and pancreas cancer (167), is 
an important source of cadmium exposure (49). In our population, the association of 
cadmium with lung and pancreas cancer remained significant after adjusting for 
smoking status and pack-years, suggesting that cadmium is an independent risk factors 
for these tumors, although we cannot discard residual confounding. Moreover, the 
associations were similar after removing the group of current smokers from the 
analyses. We also hypothesized that cadmium could act as a mediator of the association 
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between smoking and lung cancer mortality, and estimated that cadmium explained 
around 9% of the excess lung cancer mortality due to tobacco smoking. Although this 
association may seem weak, cadmium is only one of the many carcinogens present in 
tobacco smoke, and we had one single cadmium measure which could be affected by 
measurement error. 
 Women have higher cadmium internal dose compared to men (168), but it is 
unclear if higher cadmium levels in women are associated with worse health outcomes. 
In our study, there were no differences in overall or smoking-related cancer mortality by 
sex, although the association was somewhat stronger in men. In populations from 
Sweden and the US, urine cadmium has been associated with incident breast (80) and 
endometrial (169) cancer. In our study we found no association with breast cancer 
mortality, similar to NHANES III (79), although our results are limited by the small 
number of breast cancer deaths. We could not evaluate the association between urine 
cadmium and endometrial cancer mortality as only two women died from this cancer.  
 Some (76;80;165;166), but not all (170-172) epidemiological studies have found 
an association between cadmium and prostate cancer. A systematic review showed an 
increased risk of kidney cancer in cadmium exposed workers (77), but evidence from 
general populations is lacking. Cadmium has also been proposed as a contributor to 
liver cancer, with supportive evidence from China (173). Finally, there is some animal 
evidence that cadmium could induce tumors of the hematopoietic system, although 
epidemiological evidence is lacking. 
 In our study, we found no association between urine cadmium and mortality 
from kidney cancers, and observed a positive but non-significant association with liver 
and lymphohematopoietic cancer mortality. The small number of deaths in each type of 
cancers, however, limited our ability to detect associations. 
 
5.1.3 Strengths and limitations 
 Strengths of this study include the prospective design and long follow-up, the 
low rate of follow-up loses and the careful standardization and quality control of data 
collection and laboratory analyses (133;174). Furthermore, this study provides 
information on cancer mortality in American Indians, and understudied population 
whose cancer experience and cancer determinants have not been well described. The 
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relatively high concentrations of urine cadmium and arsenic in this population when 
compared to the general US population suggest that arsenic and cadmium exposure may 
be important environmental risk factors for cancer development in American Indians.  
 Our study has some limitations. First, cancer mortality is an imperfect outcome 
to study tumors with relatively good prognosis. Second, we relied on death certificates 
to identify the cause of death and had no confirmation from hospital records or cancer 
registries. Cancer deaths, however, are considered to be better coded than other causes 
of death. Third, we could not exclude participants with cancer at baseline. Analyses 
excluding cancer deaths during the 2 and 5 years of follow-up, however, showed similar 
results. Fourth, we had limited statistical power for individual cancer locations and for 
conducting effect modification analyses. Fifth, we could not account for family history 
of cancer or for clustering of arsenic exposure. Finally, we only had a single spot urine 
sample. Recent studies have indicated that urine cadmium in populations exposed to 
low-moderate levels might not reflect chronic cadmium exposure (175), although 
uncertainties in exposure measurement are likely to result in non-differential 
measurement error and to underestimate the associations. Additionally, different 
strategies to account for urine dilution, yielded similar results. In the case of arsenic, 
previous evidence in the Strong Heart Study showed relatively constant concentrations 
over a 10-year period (137), indicating that a single measure reflects long-term arsenic 
exposure in this population.  
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5.2  Discussion related to objective two 
 
 Results from MCC-Spain add strength to previous findings, while provide new 
evidence on the association between obesity and breast cancer by intrinsic subtypes. 
Our data support the hypothesis that central adiposity is a key aspect to consider when 
studying the connection between obesity and hormone-dependent tumors. In fact, even 
though BMI did not increase the risk of premenopausal breast cancer, central adiposity 
was positively associated with premenopausal breast cancer in models that took into 
account both anthropometric characteristics. In the case of PC, only central adiposity 
was associated with the risk of high-grade tumors. Our results also point out to the 
existence of differential effects of weight gain on BC risk by menopausal status and 
tumor subtype, while show that the age at maximum weight is only associated with the 
risk of high-grade prostate tumors. Finally, results for anthropometric factors earlier in 
life show that growth speed is inversely associated with the incidence of all BC 
subtypes, while does not affect PC risk.  
 
5.2.1 Obesity, other related anthropometric characteristics and breast cancer 
risk 
 Despite the numerous studies that have evaluated the relationship between 
obesity and breast cancer, major uncertainties still exist. Overall, the evidence from 
dose-response meta-analyses suggests a positive association between BMI and breast 
cancer risk in post- (176;177) but not premenopausal women (178). This opposing 
effect, which is also observed in MCC-Spain, is attributed to differences in the 
biosynthesis of estrogens by menopausal status (179). While in premenopausal women 
the ovaries are the main site of estrogen production and this process is under 
homeostatic regulation, in postmenopausal women the ovaries are replaced by 
peripheral site synthesis (180). Additionally, the greater degree of insulin resistance 
observed in postmenopausal women (181), as well as the increased tendency for young 
obese women to have anovulatory menstrual cycles (101), could act as contributing 
factors. In agreement with our findings, studies focusing on the effects of central 
adiposity on breast cancer risk have shown that while central adiposity is positively 
associated with the risk of postmenopausal breast cancer independently of BMI (182), 
this relationship is only observed in premenopausal women after adjustment for overall 
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adiposity (182-185). Although the exact mechanisms are unknown, these results 
indicate that differences in metabolic effects between general and central adiposity must 
exist.  
 Breast tumors are a very heterogeneous group of diseases with different risk 
factors, molecular and clinical characteristics. However, few reports have explored the 
possible role of obesity on specific breast cancer molecular subtypes, and when this has 
been done it has mostly relied on classifications that only considered estrogen and 
progesterone receptor status (186-188). A meta-analysis of 31 studies evaluating the 
association between relative body weight (highest versus reference categories) and 
ER/PR defined breast cancer showed that the risk for ER+/PR+ tumors decreased 
among pre- and increased among postmenopausal women (186). In order to allow for 
comparisons with this meta-analysis we reclassified our tumors according to ER and 
PR, independently of HER2 status, and found very similar results: Obese 
premenopausal women showed a decreased risk of ER+/PR+ tumors (OR=0.65; 95%CI: 
0.38-1.02) while postmenopausal obese women presented an increased risk (OR=1.79; 
95%CI: 1.21-2.13). 
 Contrary to our results, a meta-analysis on case-case and case-control studies 
focusing on the association between obesity and triple negative tumors showed that only 
obese pre-, and not postmenopausal women presented an increased risk of this particular 
cancer subtype (189). Potential factors that could link obesity to TN tumors have been 
described elsewhere, and would include insulin-related as well as inflammatory-related 
mechanisms (189). However, no biological mechanism has been proposed that could 
explain a differential effect of obesity on the risk of TN tumors by menopausal status. In 
MCC-Spain, the stronger association between obesity and breast cancer risk was 
precisely seen in postmenopausal women that developed TN tumors (OR=2.31; 95%CI: 
1.30-4.11). A recently published case-control study in Japan, also reports an increased 
risk of triple negative cancers among obese postmenopausal women (190). Because we 
only had four cases of TN tumors among obese premenopausal women, we cannot draw 
any conclusion for this specific group. 
 Overweight and obesity earlier in life have been consistently associated with a 
decreased risk of breast cancer (191-193). Although our results do not support an 
overall effect of “weight at age 20” on breast cancer risk, they suggest that early obesity 
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could decrease the risk of certain tumor subtypes in premenopausal women. In this 
sense, women who had a higher weight at age 20 or who reached their maximum weight 
earlier in life showed a decreased risk of premenopausal HER2+ or TN tumors. Results 
indicate the exact opposite effects for postmenopausal women, but the significance of 
this heterogeneity is unknown and should be evaluated in future studies. 
 Weight gain in adulthood has shown to increase the risk of postmenopausal 
breast cancer in numerous cohort studies (194-197), with evidence from a recently 
published meta-analysis that this excess risk could be confined to HR+ tumors (186). In 
contrast, most published studies on premenopausal women have either reported null 
findings (198;199) or inverse associations for weight changes and risk of HR+ tumors 
(188;190). Our results initially suggested a positive association between weight gain 
since age 20 and overall breast cancer risk in postmenopausal women, but this 
association was attenuated after accounting for current BMI. Similarly, by tumor 
subtype, a positive association with the risk of postmenopausal HR+/ERB2- tumors was 
only observed in models that did not account for BMI. Conversely, a decreased risk of 
HER2+ breast cancer was seen with increasing weight gain, a finding that to our 
knowledge has never been reported before. 
 Our results are in accordance to those of some prospective cohorts showing that 
the age at maximum height is associated with the risk of developing BC, independently 
of other pubertal/reproductive events (192;193;200;201). In this sense, earlier 
adolescent growth spurt would lead to precocious exposure of the immature breast 
tissue to hormonal and growth factors, at a time of increased susceptibility to 
carcinogenesis. Additionally, exposure to these factors during adolescence could 
influence the maturation of the hypothalamic pituitary ovarian axis, which regulates 
ovarian hormone production (202).  
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5.2.2 Obesity, other related anthropometric characteristics and prostate cancer 
risk 
 In epidemiological studies, obesity is positively associated with prostate cancer 
mortality (203), while it displays a dual effect on prostate cancer incidence, with an 
increased risk for advanced cancers and a decreased risk for non-aggressive tumors 
(111). Our results support a link between obesity and the risk of high-grade tumors, 
although only the WHR showed a statistical significant association. It has been 
suggested that the dual effect of obesity on the risk of low- and high-grade tumors could 
be due to the effect of low testosterone levels in obese men, as this hormone would lose 
the capacity of controlling the differentiation of prostate cells with the consequent 
growth of more aggressive tumors (204). Obesity, particularly central obesity, is also 
associated with increased serum levels of estradiol, insulin, insulin like-growth factors 
or cytokines, all of which have been related to an increased risk of aggressive prostate 
tumors (205). Additionally, obese men are less likely to have an early diagnosis due to 
their increased plasma volume with lower PSA levels, and their excess prostate tissue 
growth and fat deposition (206). 
 The effect of weight gain during adult life on the risk of prostate cancer has been 
less explored, and results from published studies are inconsistent, with some showing a 
positive association (207;208), while others do not (208;209). Results from the 
Multiethnic Cohort, including more than 83,000 men, showed that self-reported weight 
changes since age 21 were associated with an increased risk of prostate cancer in Whites 
and African Americans, but not in Japanese men (210). In Europe, results from the 
Nord-Trøndelag Health Study with 20,991 adult men followed-up for 9 years, showed 
no differences in prostate cancer risk with changes in measured weight (209). Similarly, 
in the Melbourne Collaborative Cohort Study, that investigates 17,045 men, weight gain 
was not associated with an increased risk of prostate cancer, although in this last study a 
deleterious effect of weight gain on prostate cancer mortality was observed (208). Our 
results failed to show a link between weight gain since age 20 and the incidence of this 
tumor. However, they support an association with age at maximum weight, suggesting 
that for PC the amount of weight gained may not be as important as the moment during 
adulthood when this occurs.  
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5.2.3 Strengths and limitations 
 Since the present results are based on a case-control study, several 
methodological limitations exist. First, self-reported data are subjected to recall bias. 
However, misclassification would be non-differential, particularly for exposures 
occurring during adolescence (age maximum height) or early adulthood (weight at age 
20, age at maximum weight). Also, by calculating BMI before the occurrence of the 
disease we are reducing the probability that the exposure is affected by the disease. In 
addition, not all variables are self-reported, and measures of central adiposity were 
obtained using standardized protocols. Second, the sample size was limited to test 
differences per tumors subtype, and this limitation is particularly relevant when 
performing stratified analyses by menopausal status. This stratification, however, is 
justified taking into account the opposite effects of obesity in pre-and postmenopausal 
women. In this sense, the results are interesting but should be considered as exploratory.  
Strengths of this investigation include the use of histologically confirmed incident 
cases, as well as the wide geographic variability, with cases recruited in many different 
Spanish regions. Additionally, we could perform analyses by intrinsic subtypes (breast) 
or Gleason scores (prostate), which is essential to correctly address the epidemiology of 
these tumors. Finally, our results are robust to various sensitivity analyses.  
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5.3 Discussion related to objective three 
 Our findings do not support an overall association between diabetes and breast 
cancer, although they suggest an increased risk of triple negative tumors in 
postmenopausal diabetic women. Women treated with insulin showed a greater 
incidence of HR+ and triple negative subtypes, while metformin use seemed to reduce 
the risk of HR+ breast cancer. Finally, treatment with hypoglycemic agents, and in 
particular sulfonylureas, was associated with an increased risk of TN tumors.  
 Regarding prostate cancer, diabetes showed a protective effect on the incidence 
of low-grade tumors, particularly in men who were normoweight and in those who were 
not taking insulin. The protective effect of diabetes was stronger as time since diagnosis 
increased.  
5.3.1 Diabetes and breast cancer risk 
 Despite a number of meta-analyses linking diabetes and breast cancer in 
postmenopausal women (211;212), results from three recently published large 
population based studies have raised uncertainty. The first of these null studies, 
retrospectively evaluated the risk of breast cancer in postmenopausal women using data 
from the Columbia Linked Health Database, which covers around 4.5 million residents 
(213). The second, based on register linkage of the Danish National Diabetes register 
and Cancer Registry, and representing the whole Danish population, found no 
association between diabetes prevalence or diabetes duration and breast cancer risk 
(214). The third, which included 68,019 postmenopausal women followed over a mean 
of 11.8 years, also failed to find an overall increased risk of breast cancer among those 
with diabetes (215). However, results from this last study were modified when diabetes 
medication was taken into account, as a reflection of the importance of considering 
diabetes treatment when studying the risk of cancer associated to this disease. In this 
sense, women under treatment with “drugs other that metformin” showed a non 
significant increased risk of breast cancer (HR: 1.16; 95%CI: 0.93-1.45), while those 
receiving metformin presented lower incidence (HR: 0.75; 95%CI: 0.57-0.99).  
 Some authors have suggested that TN tumors may be more strongly associated 
with insulin resistance (216). Our results, showing a strong association between diabetes 
and incidence of TN tumors, would support this hypothesis. However, the few previous 
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epidemiological studies that have evaluated the influence of diabetes on breast cancer 
by molecular subtypes, have yielded contradictory results. In the Carolina Breast Cancer 
Study, a population-based case-control study carried out in 24 counties in central and 
eastern North Carolina, an increased risk of basal-like breast tumors was seen in pre- 
and postmenopausal women with higher waist circumference and waist to hip ratio 
(217). Although these measures of central adiposity are well known markers of insulin 
resistance and in fact were strongly associated with a history of diabetes (217), no 
elevated prevalence of this metabolic disease was found in women with triple negative 
tumors when compared to other breast cancer subtypes. Results from the Study of 
Osteoporotic Fractures, including 8,956 women with different components of the 
metabolic syndrome showed that diabetes was associated with a borderline significant 
increased risk of ER+ and PR+ cancers, while no effect was seen for ER- or PR- (218). 
Finally, a retrospective cohort study focusing on the metabolic syndrome as a whole, 
instead of diabetes as an individual component, found a higher prevalence of this 
syndrome in patients with TN tumors, with blood glucose being an independent risk 
factor of this specific subtype (219). In light of these conflicting results, additional 
research is warranted. 
 The biological mechanisms behind a potential increased risk of breast cancer in 
women with diabetes are unknown, although are probably related to alterations in 
circulating concentrations of insulin, insulin-like growth factors and endogenous sex 
hormones. Insulin and IGF-1 receptors are frequently expressed in breast cancer cells 
(219-221), with evidence that their signaling pathways are of crucial importance in the 
role of breast cancer tumorigenesis (222;223), particularly in the case of TN tumors 
(224). Insulin also has a paracrine effect on secretion of adipokines (225;226), which 
may contribute to the increasing risk of more aggressive breast tumors (227). 
Additionally, insulin can inhibit the production of sex hormone-binding globulin in the 
liver (228), with subsequent increased levels of free estradiol and increasing 
proliferation of breast epithelial cells. 
5.3.2 Diabetes and prostate cancer risk 
 A reduced incidence of prostate cancer has been previously reported in diabetic 
men (126;229), with substantial evidence showing that the magnitude of this inverse 
association becomes higher with increasing diabetes duration (128;214;230-234). 
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Although some studies have found that diabetes may increase the risk of more 
aggressive prostate tumors (235), results from a recently published meta-analysis 
suggest that men with diabetes are protected for both low (RR:0.74; 95%CI: 0.64-0.86) 
and high-grade (RR:0.78; 95% CI 0.67-0.90) disease (236). We failed to find a 
protective effect of diabetes on the risk of high-grade tumors, even though our diabetic 
population showed a higher prevalence of PSA testing that that observed in non 
diabetics. One possible explanation is the higher prevalence of obesity among diabetic 
men, as obesity has been associated with elevated incidence of aggressive prostate 
tumors (205;237). 
 Several mechanisms for decreased prostate cancer incidence among diabetic 
men have been proposed, including the adoption of healthier lifestyles after diabetes 
diagnosis. The stronger inverse association with long-standing diabetes has been 
explained by beta cell exhaustion leading to insulin depletion and reductions in IGF-1 
(125;230;238), as these two factors have potent growth-stimulatory effects on the 
prostate (239;240). Hyperglycemia is also thought to play a major role in protecting 
against prostate cancer development (241), with epidemiological evidence showing that 
strict glycemic control increases the risk of this tumor (242). Some authors have also 
hypothesized that decreased levels of testosterone, a known stimulatory agent of 
prostate growth, may protect diabetic men from prostate cancer development. Still, it 
remains unclear if reductions in circulating testosterone are correlated with decreased 
intra-prostatic levels of this hormone (238). Finally, genetic studies have shown that 
individuals with greater susceptibility to type 2 diabetes may have a decrease risk of 
prostate cancer (243-246). 
5.3.3 Diabetes treatment and risk of hormone-dependent tumors 
 Metformin is the most commonly used drug in patients with type 2 diabetes 
(129). Experimental studies have shown that this biguanide is capable to inhibit the 
proliferation of breast (247;248) and prostate cancer cells (249). Additionally, it can 
induce apoptosis of triple negative (250) and HER2 positive cells (251), and it can 
represses the process of epithelial to mesenchymal transition (252). Interestingly, 
metformin also reduces the growth of several tumoral xenografts in mice including 
those established from breast and prostate cancer cells (249).  
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 The evidence on the association between metformin use and the risk of breast 
cancer has been mixed in epidemiologic studies (253-257). Results from most meta-
analyses have suggested a non significant decreased risk of breast cancer in metformin 
users (253;255-257), while no effect has emerged from Randomized Clinical Trials 
(253;258). Only one previous study, based on data from the Women´s Health Initiative 
clinical trials, has evaluated the incidence of specific subtypes of breast cancer in 
diabetic women under metformin treatment (215). Interestingly, findings from this study 
were very similar to those from MCC-Spain, with a protective effect of metformin only 
observed for ER+/ PR+ and not ER-/PR- tumors.  
 Regarding prostate cancer, the evidence is highly consistent, and most 
observational studies and Randomized Clinical Trials have shown no effect of 
metformin use on the risk of this tumor (253). Consistently with our findings, data from 
a recently published retrospective cohort of 119,315 Canadian men, this lack of 
association is common to low and high-grade cancers (259).  
 A small number of observational studies have shown an increased risk of several 
cancers (260-262) and overall cancer mortality (263) in diabetic patients treated with 
sulfonylurea, when compared to other treatments. However, results from Randomized 
Clinical Trials have failed to demonstrate a significant effect on the risk of overall 
cancer (258). The evidence for breast cancer and prostate cancer is scarce and the few 
existing studies have yielded inconsistent results (264-268). Our results point towards a 
possible detrimental effect of sulfonylureas on the risk of breast cancer. 
 Insulin is a well-known growth factor with particularly strong mitogenic effects 
over cancer cells (269). Results from a meta-analysis of observational studies has lately 
shown an overall increased risk of cancer in patients treated with insulin, although no 
significant increased risk of breast (RR:1.86; 95%CI:0.92-2.98) or prostate cancers 
(RR:1.17;  95%CI:0.92-1.49) was reported (270). Similarly, a recently published cohort 
study over 498,407 Taiwanese fails to encounter any association between insulin use 
and prostate cancer risk (271). Data from Randomized Controlled Trials (RCTs) do not 
support the hypothesis that insulin therapy increases the risk of cancer, although 
interpretation of their results is limited because cancer has not been the end point of 
interest. Additionally, the few RCTs on insulin therapy that have reported data on 
cancer have focused on mortality and not incidence (272).  
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 Available data from in vitro experiments suggests that insulin glargine may have 
greater proliferative effects than human insulin in some breast cancer cell lines 
(272;273). This finding is supported by observational studies showing that glargine use 
may be associated with an increased risk of breast cancer (274-276), at least at high 
doses and with long duration of treatments (128;272). A population based cohort with 
more than 27,000 users of insulin glargine and 100,757 users of NPH has shown a 30% 
increased risk of breast cancer in patients with ever use of glargine (RR:1.3: 95%CI: 
1.0-1.8) (277). Some experimental studies also suggest that glargine may have a potent 
mitogenic activity on prostate cancer cells (278), but the evidence from epidemiological 
studies is less consistent, with some studies showing an increased risk (276;279), while 
others have not (275;277;280).  
 
5.3.4 Strengths and limitations 
 This is the first population-based study that evaluates the association between 
diabetes and cancer in the Spanish population. Similarly to what it was explained in 
objective 2, our main strength is that we have histologically confirmed incident cases 
and that we have been able to classify them according to their receptor status (breast) or 
Gleason scores (prostate). Very few observational studies have previously evaluated the 
association between diabetes and breast cancer subtypes, and our results suggest the 
importance of this approach. 
 
 This study also has several limitations. First, diabetes history is self-reported and 
so it is subject to recall bias. According to the International Diabetes Federation, around 
35% of the European diabetic population is unaware of having this condition (281), and 
similar rates have been described in Spain (282). However, we expect under-diagnosis 
not to be so important in our population because participants had frequent contact with 
the health system, as reflected by their high prevalence of screening practices. 
Additionally, results from a meta-analysis on the association between diabetes and 
breast cancer showed that findings were unchanged when the diagnosis of diabetes was 
self-reported or confirmed with medical records (212). Second, we were limited by the 
sample size, particularly for evaluating certain subgroup associations. Third, our dataset 
does not allow us to differentiate between type 1 or type 2 diabetes, although by 
excluding all cases diagnosed of diabetes before the age of 45 we are limiting the 
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probability of including cases of type 1 diabetes. Fourth, it is hard to disentangle the 
effects of diabetes treatment from those of the disease itself. As an example, diabetic 
patients receiving insulin are a subgroup with very specific characteristics, they usually 
have more severe forms of diabetes and greater prevalence of comorbidities that can 
lead themselves to an increased cancer risk. Additionally, individuals receiving insulin 
usually visit their doctors more frequently, and this may increase their probability of 
screening and cancer detection. Finally, we do not have information on glycaemic 
control, and this has been shown to be an important independent predictor of cancer risk 
(283). 
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6  CONCLUSIONS 
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Objective 1:  
Conclusion 1: Low to moderate exposure to inorganic arsenic was prospectively 
associated with increased mortality from lung, prostate and pancreas tumors, and 
decreased mortality from cancers of the lymphatic and hematopoietic tissue 
Conclusion 2: Low to moderate exposure to cadmium was prospectively associated 
with increased mortality from overall cancer, smoking-related tumors and lung and 
pancreatic cancer. 
Conclusion 3: The relatively high concentrations of urine cadmium and arsenic in the 
studied communities, when compared to the general US population, suggest that arsenic 
and cadmium exposure may be important environmental risk factors for cancer 
development in American Indians.  
 
Objective 2:  
Conclusion 1: In postmenopausal women, obesity and central adiposity were associated 
with an increased risk of breast cancer, and this association was similar for all tumor 
subtypes. The age at maximum height was associated with a decreased risk of all tumor 
subtypes, while the age at maximum weight was inversely associated only with the risk 
of triple negative tumors. Finally, differential effects of weight gain were observed by 
tumor subtype.   
Conclusion 2: In premenopausal women, central adiposity was associated with an 
increased risk of breast cancer in models that accounted for body mass index, while 
obesity early in life was mainly associated with a decreased risk of more aggressive 
tumor subtypes.  
Conclusion 4: In men, the age at maximum weight and the waist to hip ratio were 
positively associated with the risk of high-grade prostate tumors.  
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Objective 3: 
Conclusion 1: In postmenopausal women, previous diagnosis of type 2 diabetes was 
associated with an increased risk of triple negative breast tumors.  
Conclusion 2: Insulin use was associated with an overall increased risk of breast 
cancer. Metformin use was associated with a decreased risk of HR+/HER2- tumors, 
while use of sulfonylurea was associated with an increased risk of TN cancers.  
Conclusion 3: For prostate cancer, a decreased risk of low-grade tumors was observed 
in normoweight men with diabetes, and this protective effect was stronger as time since 
diagnosis increased.  
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CURRENT POSITION 
 
Research personnel contracted by the Carlos III Health Institute (“Río Hortega” contract, co-funded by the 
European Regional Development Fund).  
Address: Environmental and Cancer Epidemiology Unit 
National Center for Epidemiology 
Carlos III Institute of Health 
C/ Sinesio Delgado, 6, 28029  
Madrid, Spain 
 
Telephone (work): 00-34-91-822-2688  
E-mail: esthergge@gmail.com  
Advisor: Marina Pollán (mpollan@isciii.es) 
 
EDUCATION 
2009-2012 
 
Diploma of Advanced Studies. Doctoral program in Public Health. 
Autonomous University of Madrid, Spain. 
2007- 2010 
 
Medicine Residency in Preventive Medicine and Public Health*.  
Ramón y Cajal Hospital, Madrid 
*4-year specialized degree program accredited by the Spanish Ministry of Health and Education 
2007-2009 
 
Graduate Diploma in Design and Statistics in Health Science 
Autonomous University of Barcelona 
2006 -2007 
 
Master of Public Health 
National School of Public Health. Carlos III Health Institute. Madrid (Spain) 
1999 -2005 
 
Degree in Medicine and Surgery*. (MD.) 
School of Medicine  
Autonomous University of Madrid, Madrid, Spain 
*6-year Spanish professional degree in Medicine and Surgery.  
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PROFESSIONAL EXPERIENCE 
  
2011 –2013 “Río Hortega” health research competitive contract (National Center for 
Epidemiology). This included a six-month training fellowship at the Division of 
Occupational and Environmental Health Unit at John Hopkins Bloomberg school of 
Public Health. 
  
2010 Research personnel contracted by CIBERESP (Ciber for Epidemiology and 
Public Health)  
  
2007- 2010 Residency in Preventive Medicine and Public Health  
Hospital Universitario Ramón y Cajal, Madrid (Spain). 
 
COMPETITIVE RESEARCH PROJECTS  
 
Project title: Role of metals in the genesis of prostate cancer in Spain: metal-MCC-Spain. PI12/00150 
Duration: 2013-2015 
Budget: 188155 €. 
Principal Investigator: Beatriz Pérez-Gómez  
 
Project title: Epidemiologic Study of night shift work, circadian disruption, genetic susceptibility and breast and 
prostate cancer risk. PI11/01889 
Duration: 2012-2014 
Budget: 181091 €. 
Principal Investigator: Manolis Kogevinas  
 
Project title: Etiopathogeny of gastric Cancer in Spain: Possible interactions microbiota-environment in a 
population-based multicenter case-control study (MCC-Spain Gastric Cancer). PI11/01403 
Duration: 2012-2014 
Budget: 210320 €. 
Principal Investigator: Nuria Aragonés Sanz. 
  
TEACHING EXPERIENCE  
  
Academic course 
2010-2011 
Master in Public Health (National School of Health) 
Epidemiology and Biostatistics courses. 
  
Academic course 
2010-2011 
International Master in Public Health (National School of Health) 
Epidemiology and Biostatistics courses 
Master in Public Health and Field Epidemiology Training Program (National 
School of Health)Outbreak investigations in Public Health. 
  
Academic course 
2009-2010 
Master Program in Nursing, European University (Alcala de Henares, Madrid) 
SPSS in Medical Science 
Clinical Trials: evidence based medicine. 
 
 
2007 “Food Manipulation Course”. Instituto Madrileño de Administración Pública 
(IMAP) Hospital Ramón y Cajal. Madrid, November 2007 (20 h). 
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RESEARCH CENTER NETWORKS 
 
Biomedical Research Centre Network for Epidemiology and Public Health (CIBEResp) 
 
 
GRANTS FOR ACADEMIC STUDIES ABROAD 
INVESTIGATION AWARDS  
 
*CiberESP award for the Thesis Project “Metal Exposures, Endocrine Factors and Cancer Risk”. Encuentro para 
la Excelencia de la Investigación en Salud Pública 2013. Lazareto de Maó, Menorca 
 
*7th Conference on Metal Toxicity and Carcinogenesis 2012: “Best poster” award.  
* Enrique Nájera award for the research project entitled “Metalohormones and cancer”. National School of 
Public Health 2011. 6.000 euros award to help young epidemiologists to implement a research project. 
Spanish Society of Epidemiology Award for Young Epidemiologist – 1st place for the project entitled “Gastric 
Cancer mortality trends in Spain: Regional differences and disease burden due to premature death, 1975-2005”. 
Gerona 2008. XXVI Reunión Científica de la Sociedad Española de Epidemiología.  
Spanish Society of Epidemiology Award for Young Epidemiologist – 1st place for the project entitled “Heavy 
metals in breast milk and its relationship with sociodemographic variables, lifestyle factors and diet: BioMadrid 
proyect”. Córdoba, Octubre 2007. XXV Reunión Científica de la Sociedad Española de Epidemiología.  
First place ACCESIT award. X for the project entitled “Research study on Medical records: documentation and 
proper vaccine administration in splenectomized at the Severo Ochoa Hospital” XVI Jornadas de Vacunación 
Internacional sobre Actualización de Vacunas. Hospital Universitario 12 de octubre. 
*AWARDS RELATED TO THIS DOCTORAL THESIS 
  
2010 European Educational Program in Epidemiology (EEPE).  
Florence. Italy. 
Grant funded by the Spanish Society of Epidemiology.  
 
2009 
 
John Hopkins University. Bloomberg School of Public Health 
(Department of Environmental Health Science).  
Grant funded by the Spanish Ministry of Health 
 
2000-2001 Erasmus program. Facoltá di Medicina e Chirurgia 
Universitá Degli Studi di Parma. Italy. 
(1 academic year) 
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R, Guinó E, Pollán M. Type 2 diabetes and hormone-dependent tumours: MCC-SPAIN. Sociedad Española 
de Epidemiología. Granada. 2013 
 
García-Esquinas E, Jiménez-Moleón JJ, Linares C, Aragonés M, Kogevinas M, Molina AJ, Guevara M, 
Moreno V, Pollán M. Type 2 diabetes and digestive tumours: MCC-SPAIN. Sociedad Española de 
Epidemiología. Granada. 2013 
Linares C., García-Esquinas E, Castaño G, Fernández T, Guevara M, Llorca J, Peiró R, Fernández-Somoano 
A, Aragonés N. Anthropometric factors and gastroesophageal cancer: MCC-SPAIN. Sociedad Española de 
Epidemiología. Granada. 2013 
García-Esquinas E, Loeffler L, Weaver V, Fadrowski J, Navas-Acién A. Kidney function and tobacco 
smoke exposure in US adolescents. International Society for Environmental Epidemiology. Basel, 2013. 
** García-Esquinas E, Pollán M , Umans JG, Francesconi KA, Goessler W, Guallar E, Farley J, Yeh J, Best 
LG, Navas-Acien A. Arsenic exposure and cancer mortality in a US-based Prospective Cohort Study: the 
Strong Heart Study. International Society for Environmental Epidemiology. Basel, 2013. 
Fernández-Navarro P, García-Pérez J., González-Sánchez M., García-Esquinas E., López-Abente G., Astray 
J., Fernández M.A., Martínez M., Aragón N.. Association between blood mercury levels and proximity to 
industrial facilities. Environmental Health 2013. Boston, 2013. 
** García-Esquinas E, Pollán M , Umans JG, Francesconi KA, Goessler W, Guallar E, Farley J, Yeh J, Best 
LG, Navas-Acien A. Arsenic exposure and cancer mortality in a US-based Prospective Cohort Study: the 
Strong Heart Study. 7th conference on Metal Toxicity and Carcinogenesis. Alburquerque, 2012 
** García-Esquinas E, Tellez-Plaza M, Pollán M , Umans JG, Francesconi KA, Goessler W, Guallar E, 
Farley J, Yeh J, Best LG, Navas-Acien A. Cadmium exposure and cancer mortality in a US-based Prospective 
Cohort Study: the Strong Heart Study. 7th conference on Metal Toxicity and Carcinogenesis. Alburquerque, 
2012 
** García-Esquinas E, Lope V, Pérez- Gómez B, Castaño-Vinyals G, Gómez-Acebo I, Altzibar J, Ardanaz 
J,Martín V, Tardón A, Alguacil J, Crous-Bou M, Peiró R, Jiménez-Moleón JJ, Pollán M. Fat distribution and 
adult weight gain as risk contributors in hormone-dependent tumors: MCC-Spain. International Society for 
Environmental Epidemiology. South Carolina, 2012. 
Lope V, García-Esquinas E, Aragonés N, Kogevinas M, Dierssen-Sotos T ,Altzibar J, Guevara M, Martin V, 
Tardón A, Alguacil J, Crous-Bou M, Salas D, Jiménez-Moleón JJ, Pollán M. Birth and childhood 
characteristics and risk of adult hormone-dependent cancers: MCC-Spain. International Society for 
Environmental Epidemiology. South Carolina, 2012. 
Benavente Y, Cassabonne D, Pérez-Gómez B, García-Esquinas E, Moreno V, Souto A, de Sanjosé S, Martín 
V. Antecedentes familiares de cáncer en los progenitores de los controles del proyecto MCC-Spain: resultados 
preliminares. XXV Reunión SEE, Santander, 2012. 
Seoane-Mato D, García-Esquinas E, Pérez-Gómez B, Romero B, Del Campo R, Aragonés N. Systematic 
revisión of the prevalence of Helicobacter Pylori in Spain. XXIX Reunión SEE-SESPAS, Madrid. 2011. 
García-Esquinas E, Pérez-Gómez B, López V, Aragonés N, Boldo E, Sierra A, Tabernero A, Burgos J, 
Kogevinas M, Pollán M. Prostate cancer and its association with birth factors: MCC-Spain. XXIX Reunión 
SEE-SESPAS, Madrid. 2011. 
Garcia-Esquinas E, Apostolou A, Fadrowski J, McClain P, Weaver V., Navas-Acien A.Secondhand tobacco 
smoke: a source of lead exposure in US children and adolescents. Oral communication. International Society 
for Environmental Epidemiology. Barcelona, 2010. 
García-Esquinas E, Aragonés N, Fernández MA, Pérez-Gómez B et al. Mercury, lead and cadmium in 
human milk in relation to diet, lifestyle and socio-demographic factors in Madrid, Spain. International Society 
for Environmental Epidemiology. Dublin, 2009. 
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MJ Perez_Elias, Gutierrez C, Casado J, Muriel A, Garcia-Esquinas E. et al, Agreement Degree between two 
genotype interpretation Systems, Tipanavir (TPV), and Darunavir (DRV) Validated Weight Scores (WS) and 
Standford HIVdv Program. 5th IAS conference on HIV Pathogenesis, Treatment and Prevention,Cape Town, 
2009. 
García-Esquinas E. “Gastric Cancer mortality trends in Spain: Regional differences and disease burden due to 
premature death, 1975-2005”. XXVI Reunión Científica de la Sociedad Española de Epidemiología. Gerona, 
2008.  
Paniagua-A, Varela C, Aragon C, García-Esquinas E., Moya JL, Ruiz S, Lahera M. Estudio Caso-Control de 
La función valvular cardíaca en pacientes tratados con dopaminérgicos ergóticos o similares con 
hiperprolactinemia. 50 Congreso Nacional de Endocrinología y Nutrición SEEN, Bilbao 2008. 
 
 García-Esquinas E., Robustillo Rodela A., Díaz-Agero C., Saa Requejo C. et al. Pacientes colonizados por 
Staphilococo Meticilin Resistente: ¿Cuándo levantar el aislamiento? Experiencia del Hospital Ramón y Cajal. 
IX Jornadas Nacionales Sobre Avances en Medicina Preventiva. Murcia 2008. España. 
García-Esquinas E, Zuza I, Martínez B. Estudio sobre la documentación y adecuación de las vacunaciones 
en pacientes esplenectomizados en el Hospital Severo Ochoa. Oral communication. IX Jornadas 
Internacionales Sobre Actualización en Vacunas. Hospital Universitario 12 de Octubre. Madrid, 2008.  
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PUBLICATIONS  
 
García-Esquinas E, Pérez-Gómez B, Fernández-Navarro P, Fernández MA, de Paz C, Pérez-Meixeira A, Gil 
E, Iriso A, SanzJC, Astray J, Cisneros M, de Santos A, Asensio A, García-Sagredo JM, Frutos García J, Vioque 
J, López-Abente G, Pollán M, González MJ, Martínez M, Aragonés N. Lead, mercury and cadmium in 
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Cancer Research Group GEICAM) 2013 
García-Esquinas E*, Apostolou A*, Fadrowski JJ, McClaine P, Weaver VM, Navas-Acien A. Secondhand 
Tobacco Smoke: A source of Lead Exposure in US Children and Adolescents. Am J Public Health. 2011. * 
These authors contributed equally to this project. 
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85(2) :268-76 
García-Esquinas E, López-Gay D. Paludismo en la Comunidad de Madrid años 2004 - 2008. 
Boletín Epidemiológico de la Comunidad de Madrid Nº 9. Volumen 16. Septiembre 2010. 
García-Esquinas E, Pérez-Gómez B, Pollán M, Boldo E. Gastric cancer mortality trends in Spain, 1976-2005, 
differences by autonomous region and sex. BMC Cancer. 2009 Sep 28;9:346. 
García-Esquinas E, Zuza Santacilia I, Martínez Mondéjar B. Documentation and proper vaccine 
administration in splenctomized patients. Med Clin (Barc). 2009 Apr 8. 
García-Esquinas E, Gènova Maleras R, Esteban Vasallo MD, Domínguez Berjón MF. Objetivo 3. Iniciar la 
vida en buena salud. Informe del Estado de Salud de la Población de la Comunidad de Madrid 2009. Dirección 
General de Atención Primaria. Consejería de Sanidad, Comunidad de Madrid, 2009:99-112. 
García-Esquinas E., Aragonés N, Fernández MA, Pérez-Gómez B, González MJ, Iriso A, Astray J, Pollán M, 
Martínez M. Mercury, Lead and Cadmium in Human Milk in Relation to Diet, Lifestyle and Socio-
Demographic Factors in Madrid, Spain. Epidemiology. 2009 Nov 20;6: p S151. 
García-Esquinas E, Aragonés N, Fernández M, Astray J, Pérez-Gómez B, Martínez M, García JF, Gil E, 
González MJ et al. Metales pesados en leche materna y su relación con variables socio-demográficas, hábitos y 
dieta: Proyecto Bio-Madrid. Gac Sanit.21:55, 2007. 
Manuscripts accepted for publication: 
***García-Esquinas E, Pollan M, Téllez-Plaza M, Francesconi K, Goessler W, Guallar E, Umans JG, Yeh J, 
Best L, Navas-Acién A.Cadmium Exposure and Cancer Mortality in a Prospective Cohort: the Strong Heart 
Study. Accepted for publication on Environmental Health Perspectives, June 2013 (Ref 13-06587) 
Manuscripts under review: 
García-Esquinas E, Fernández-Navarro P, Pérez-Gómez B, Fernández MA, de Paz C, Pérez-Meixeira A, Gil 
E, Iriso A, SanzJC, Astray J, Cisneros M, de Santos A, Asensio A, García-Sagredo JM, Frutos García J, Vioque 
J, López-Abente G, Pollán M, González MJ, Martínez M, Aragonés N. Newborns and low to moderate prenatal 
environmental lead exposure: might fathers be the key?. Sent on July 2013 to Environmental Research. 
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Manuscripts already drafted as a first author waiting for the MCC-Spain Steering Committee approval: 
***Associations of diabetes and diabetes treatment with breast and prostate cancer incidence by histological 
subtype: a case-control study (MCC-Spain) 
***Obesity, fat distributio, weight changes in adulthodd and risk of hormone-dependent tumors in a multicenter 
case-control study (MCC-Spain). 
*** MANUSCRIPTS RELATED TO THIS DOCTORAL THESIS 
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CONTINUOUS EDUCATION AS A GRADUATE STUDENT 
 
2012 Epigenetics – Biology, Methods, and Biostatistics 
Held at the Annual Conference of the International Society for Environmental Epidemiology (ISEE) 
 
2012 DAGs in Everyday Life: Design, Implementation, and Interpretation 
Held at the Annual Conference of the International Society for Environmental Epidemiology (ISEE) 
 
2012 Immunology of environmental diseases. 
Held at the Bloomberg School of Public Health 
  
2012 Environmental and occupational epidemiology. 
Held at the Bloomberg School of Public Health 
 
2011  
 
Statistical analyses in genetic epidemiology using R  
Held at the Center for Research in Environmental Epidemiology (CREAL)  
Total hours: 20 hours 
 
2011 
 
Introduction to Geographic Information Systems 
Held at the Spanish National School of Public Health, Madrid (Spain). 
Total Hours: 20 h 
 
2011 
 
Stata Corp’s Net Course 151. Introduction to Stata Programming  
Six weeks on line course 
 
2010 
 
Statistical analyses with R  
Held at the Spanish National School of Public Health, Madrid (Spain). 
Total Hours: 30 h. 
 
2010 
 
Basics of Access  
Held at the Spanish National School of Public Health, Madrid (Spain). 
Total Hours: 20 h. 
 
2009  
 
Epidemiologic Methods I y Epidemiologic Methods II. *   
Held at the Bloomberg School of Public Health 
 
2009  
 
Statistical Methods In Public Health I y Statistical Methods In Public Health II 
Held at the Bloomberg School of Public Health 
 
2008- 2009 
 
Multivariable Regression Analysis in Health Sciences 
Held at the Autonomous University of Barcelona (Spain) 
Total hours: 325 h. 
2009 Multiple Regression Analysis. Logistic Regression using SPSS 
Held at the Ramon y Cajal Hospital, Madrid (Spain) 
Total hours: 32 h. 
 
2009 Demography and Health 
Held at the National Public Health Institute, Madrid (Spain) 
Total hours: 45 h. 
 
2008 
 
Methodological and conceptual advances in Clinical research investigation and EBM 
Held at the Lain Entralgo Agency, Madrid (Spain) 
Total hours: 18 h. 
 
2008  Survival analysis. Kaplan-Meier survival curves and Cox Regression  
Held at the Lain Entralgo Agency, Madrid (Spain) 
Total hours: 32 h. 
 
2008 Biomonitoring human exposure to environmental pollutants in Spain 
Held at the International University of Andalucía, Sevilla (Spain) 
Total hours: 30 h. 
 
2008 Poisson regression 
Held at the Spanish National School of Public Health, Madrid (Spain). 
Total Hours: 30 h. 
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2008 Meta-analysis 
Held at the Spanish National School of Public Health, Madrid. (Spain).  
Total Hours: 30 h. 
 
2007-2008 Fundamental Statistics 
Held at the Autonomous University of Barcelona (Spain.) 
Total hours: 325 h. 
 
2008 Writing and publishing Scientific Papers 
Held at the Spanish National School of Public Health, Madrid. (Spain). 
Total hours: 30 h. 
 
2008 System Dynamics Application in Epidemiology 
Held at the Spanish National School of Public Health, Madrid (Spain). 
Total Hours: 30 h. 
 
2008 Surveillance and Infection Control 
Held at the Public Health Institute, Madrid. (Spain) 
Total hours: 25 h. 
 
2008 Biostatistical Methods in Epidemiology 
Held at the Autonomous University of Madrid. (Spain) 
Total hours: 30 h. 
 
2007 Burden of Disease: Methodology and Applications  
Held at the Spanish National School of Public Health, Madrid. (Spain). 
 Total hours: 20 h. 
 
2007 Data Analysis with SPSS 
Held at Autonomous University of Barcelona (Spain.) 
Total Hours: 50 h. 
 
2006 Course in bibliographic research 
Held at the Lain Entralgo Agency, Madrid (Spain) 
Total hours: 10 h. 
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COMPUTER SKILLS 
 
Statistical packages  Stata (advanced), R, SPSS, Epiinfo. 
 
Operative systems Microsoft Windows. 
 
 
LANGUAGE SKILLS 
 
Spanish Mother tongue. 
 
English 
 
Excellent written and spoken communication skills. 
 
Italian 
 
Excellent written and spoken communication skills.  
 
French 
 
Basic  
 
 
OTHER  
 
Acupunture Degree by the Complutense University of Madrid.  
 
  
147 
 
RESIDENCY ROTATIONS 
 
From March 2012- 
September 2012 
 
Fellowship at Johns Hopkins Bloomberg School of Public Health 
Department of Environmental Health Science 
Advisor: Ana Navas-Acien. 
 
From March 2010-May 
2010 
 
 
 
From January 2010-
March 2010 
 
 
From August 2009-
Decembre 2009 
 
 
From May 2009 to 
August 2009 
Applied epidemiology department. National Center for Epidemiology 
 Changes in mortality during transmission of pandemic influenza 
Advisor: Fernando Simón Soria. 
 
 
Transmissible diseases section of the National Public Health Institute. 
Study of imported malaria in travelers and immigrants.  
 
 
Fellowship at Johns Hopkins Bloomberg School of Public Health 
Department of Environmental Health Science 
Advisor: Ana Navas-Acien. 
 
 
Department of Health. National Public Health Institute. Madrid 
Analysis of Infant Mortality Rates in Madrid Autonomous Community 
Advisor: Ricard Génova Maleras. 
 
From January 2009 to 
May 2009 
 
Biostatistics Unit, Ramon y Cajal Hospital. 
Consultant  
Analyst on the International Europreval Project: socio-economic impact of food allergies in Spain 
Advisor: Victor Abraira. 
 
From August. 2008 to 
December 2008 
 
Rotation in Primary Health Care Coordination Area, Area 7 of Madrid Autonomous 
Community. 
 
From April.2008 to 
August. 2008 
 
Resident-Fellow. National Center of Epidemiology, Carlos III Institute, Madrid (Spain). 
Area of Environmental Epidemiology and Cancer. 
Advisor: Nuria Aragonés. 
 
 
 
   
